wint20190331

0001437749-19-010506.txt : 20190520 0001437749-19-010506.hdr.sgml : 20190520 20190520164739 ACCESSION NUMBER: 0001437749-19-010506 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190520 DATE AS OF CHANGE: 20190520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WINDTREE THERAPEUTICS INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26422 FILM NUMBER: 19839417 BUSINESS ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 BUSINESS PHONE: 2154889300 MAIL ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ DATE OF NAME CHANGE: 19971201 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 10-Q 1 wint20190331_10q.htm FORM 10-Q wint20190331_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-26422

Windtree Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		94-3171943
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)
	2600 Kelly Road, Suite 100
	Warrington, Pennsylvania 18976-3622
	(Address of principal executive offices)

(215) 488-9300

(Registrant’s telephone number, including area code)

__________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act:

Common stock, $0.001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒ NO ☐

Table of Contents

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

As of May 10, 2019, there were outstanding 32,188,855 shares of the registrant’s common stock, par value $0.001 per share.

Table of Contents

Table of Contents

PART I - FINANCIAL INFORMATION

		Page

Item 1.	Financial Statements	3

	CONDENSED CONSOLIDATED BALANCE SHEETS
	As of March 31, 2019 (unaudited) and December 31, 2018	3

	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
	For the Three Months Ended March 31, 2019 and 2018	4

	CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)
	For the Three Months Ended March 31, 2019 and 2018	5

	CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (unaudited) For the Three Months Ended March 31, 2019 and 2018	6

	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) For the Three Months Ended March 31, 2019 and 2018	7

	Notes to Condensed Consolidated Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24

Item 4.	Controls and Procedures	24

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	25

Item 6.	Exhibits	25

Signatures		27

Table of Contents

Unless the context otherwise requires, all references to “we,” “us,” “our,” and the “Company” include Windtree Therapeutics, Inc., and its wholly-owned subsidiaries, CVie Investments Limited, CVie Therapeutics Limited; and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts and include, without limitation, statements concerning our business strategy, outlook, future milestones, goals and objectives, and our financial plans and future financial condition, including the period of time during which our existing resources will enable us to fund our operations and continue as a going concern. Forward-looking statements also include our expectations about the timing and anticipated outcomes of submitting regulatory filings in the United States (US) and other markets for our products under development; our research and development programs, including planned development activities, anticipated timing of clinical trials and potential development milestones; manufacturing plans for our drug products, active pharmaceutical ingredients, materials and our aerosol delivery system (ADS); and our plans regarding potential strategic alliances, collaboration agreements, including licensing opportunities, and other potential strategic transactions (including without limitation, by merger, acquisition or other corporate transaction).

We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Examples of such risks and uncertainties include, but are not limited to the following:

●

our ongoing capital resource requirements and our ability to raise funds to meet such requirements;

●

our ability to successfully identify and enter into strategic and other non-dilutive transactions;

●

our ability to successfully execute development activities;

●

our ability to successfully integrate our company following our acquisition of CVie Investments;

●

risks related to manufacturing active pharmaceutical ingredients, drug product, medical devices and other materials we need; and

●

other risks and uncertainties detailed in Risk Factors and elsewhere in our Annual Report on Form 10-K, and in the documents incorporated by reference therein.

Table of Contents

Pharmaceutical, biotechnology and medical technology companies have suffered significant setbacks conducting clinical trials, even after obtaining promising earlier preclinical and clinical data. In addition, data obtained from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. After gaining approval of a drug product, medical device or combination drug/device product, pharmaceutical and biotechnology companies face considerable challenges in marketing and distributing their products and may never become profitable.

The forward-looking statements contained in this report or the documents incorporated by reference herein speak only as of their respective dates. Factors or events that could cause our actual results to differ may emerge from time to time and it is not possible for us to predict them all. Except to the extent required by applicable laws, rules or regulations, we do not undertake any obligation to publicly update any forward-looking statements or to publicly announce revisions to any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Trademark Notice

AEROSURF®, SURFAXIN®, WINDTREE THERAPEUTICS™, and WINDTREE™ are registered and common law trademarks of Windtree Therapeutics, Inc. (Warrington, PA).

Table of Contents

ITEM 1. Financial Statements

WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except share data)

	March 31, 2019			December 31, 2018
	Unaudited
ASSETS
Current Assets:
Cash and cash equivalents	$	2,053		$	11,187
Available-for-sale marketable securities		13,514			13,959
Prepaid expenses and other current assets		502			507
Total current assets		16,069			25,653

Property and equipment, net		826			802
Restricted cash		171			171
Operating lease right-of-use assets		1,788			-
Intangible assets		77,090			77,090
Goodwill		15,682			15,682
Total assets	$	111,626		$	119,398

LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	1,417		$	3,420
Collaboration and device development payable, net		1,939			2,576
Accrued expenses		5,247			6,465
Operating lease liabilities - current portion		730			-
Deferred revenue		158			198
Loan payable		7,469			7,974
Total current liabilities		16,960			20,633

Operating lease liabilities - non-current portion		1,251			-
Restructured debt liability - contingent milestone payments		15,000			15,000
Deferred tax liabilities		15,356			15,476
Other liabilities		63			175
Total liabilities		48,630			51,284

Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2019 and December 31, 2018		-			-
Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018; 32,188,929 and 32,133,263 shares issued at March 31, 2019 and December 31, 2018, respectively; 32,188,855 and 32,133,189 shares outstanding at March 31, 2019 and December 31, 2018, respectively		32			32
Additional paid-in capital		730,162			728,783
Accumulated deficit		(664,184	)		(657,647	)
Accumulated other comprehensive income		40			-
Treasury stock (at cost); 74 shares		(3,054	)		(3,054	)
Total stockholders' equity		62,996			68,114
Total liabilities & stockholders' equity	$	111,626		$	119,398

See notes to condensed consolidated financial statements

Table of Contents

WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

	Three Months Ended
	March 31,
	2019			2018

Revenues:
License revenue with affiliate	$	40		$	204
Total revenues		40			204

Expenses:
Research and development		3,342			3,118
General and administrative		3,355			1,926
Total operating expenses		6,697			5,044
Operating loss		(6,657	)		(4,840	)

Other income / (expense):
Interest income		60			4
Interest expense		(136	)		(90	)
Other income		196			414
Other income / (expense), net		120			328

Net loss	$	(6,537	)	$	(4,512	)

Net loss per common share
Basic and diluted	$	(0.20	)	$	(1.40	)

Weighted average number of common shares outstanding
Basic and diluted		32,142			3,227

See notes to condensed consolidated financial statements

Table of Contents

WINDTREE THERAPEUTICS, INC.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands, except per share data)

	Three Months Ended
	March 31,
	2019			2018

Net loss	$	(6,537	)	$	(4,512	)
Other comprehensive income:
Unrealized gain on marketable securities		40			-

Comprehensive loss	$	(6,497	)	$	(4,512	)

See notes to condensed consolidated financial statements

Table of Contents

WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

(Unaudited)

(in thousands)

	Preferred Stock				Common Stock												Treasury Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income		Shares		Amount			Total

Balance - December 31, 2017		3	$	-		3,227	$	3	$	616,245		$	(637,114	)	$	-		-	$	(3,054	)	$	(23,920	)
Net Loss		-		-		-		-		-			(4,512	)		-		-		-			(4,512	)
Share Purchase Agreement, April 2018		-		-		-		-		(52	)		-			-		-		-			(52	)
Stock-based compensation expense		-		-		-		-		418			-			-		-		-			418
Balance - March 31, 2018		3	$	-		3,227	$	3	$	616,611		$	(641,626	)	$	-		-	$	(3,054	)	$	(28,066	)

	Preferred Stock				Common Stock												Treasury Stock
	Shares		Amount		Shares		Amount		Additional Paid-in Capital			Accumulated Deficit			Accumulated Other Comprehensive Income		Shares		Amount			Total

Balance - December 31, 2018		-	$	-		32,133	$	32	$	728,783		$	(657,647	)	$	-		-	$	(3,054	)	$	68,114
Net Loss		-		-		-		-		-			(6,537	)		-		-		-			(6,537	)
Vesting of restricted stock units		-		-		56		-		-			-			-		-		-			-
Withholding tax payments related to net share settlements of restricted stock units		-		-		-		-		(151	)		-			-		-		-			(151	)
Stock-based compensation expense		-		-		-		-		1,530			-			-		-		-			1,530
Unrealized gain on marketable securities		-		-		-		-		-			-			40		-		-			40
Balance - March 31, 2019		-	$	-		32,189	$	32	$	730,162		$	(664,184	)	$	40		-	$	(3,054	)	$	62,996

See notes to condensed consolidated financial statements

Table of Contents

WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Three Months Ended
	March 31,
	2019			2018
Cash flows from operating activities:
Net loss	$	(6,537	)	$	(4,512	)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of deferred revenue		(40	)		(204	)
Depreciation		50			41
Amortization of operating lease right-of-use assets		192			-
Amortization of debt discount		55			-
Stock-based compensation		1,530			418
Realized gain on investments		(11	)		-
Changes in:
Prepaid expenses and other current assets		5			293
Accounts payable		(2,003	)		1,635
Collaboration and device development payable		(692	)		49
Accrued expenses		(1,118	)		(266	)
Operating lease liabilities		(214	)		-
Other liabilities		24			-
Net cash used in operating activities		(8,759	)		(2,546	)

Cash flows from investing activities:
Purchase of property and equipment		(74	)		-
Proceeds from sale of marketable securities		499			-
Net cash provided by investing activities		425			-

Cash flows from financing activities:
Proceeds from loan payable, net of expenses		-			2,500
Principle payments on loan payable		(447	)		-
Payment for taxes related to net share settlements of restricted stock units		(151	)		-
Net cash (used in) / provided by financing activities		(598	)		2,500
Effect of exchange rate changes on cash and cash equivalents		(202	)		-
Net decrease in cash and cash equivalents		(9,134	)		(46	)
Cash, cash equivalents and restricted cash - beginning of year		11,358			2,040
Cash, cash equivalents and restricted cash - end of year	$	2,224		$	1,994

See notes to condensed consolidated financial statements

Table of Contents

Notes to Condensed Consolidated Financial Statements (unaudited)

Note 1 –

The Company and Description of Business

Windtree Therapeutics, Inc. (referred to as “we,” “us,” or the “Company”) is a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute pulmonary and cardiovascular diseases. Historically, our focus has been on the development of our proprietary KL4 surfactant technology and aerosol delivery system (ADS) technology for the treatment and/or prevention of respiratory distress syndrome (RDS) in premature infants. On December 21, 2018, we entered into an Agreement and Plan of Merger (the CVie Acquisition) with CVie Investments Limited (CVie Investments), an exempted company with limited liability incorporated under the laws of the Cayman Islands, pursuant to which we issued shares of our common stock, par value $0.001 per share (common stock), to CVie Investments’ former shareholders, at an exchange ratio of 0.3512 share of common stock for each share of CVie Investments outstanding prior to the merger, resulting in the issuance of 16,265,060 shares of common stock in exchange for the outstanding shares of CVie Investments. Since the CVie Acquisition, which closed on December 21, 2018, we have operated CVie Investments, and its wholly-owned subsidiary, CVie Therapeutics Limited (CVie Therapeutics), a Taiwan corporation organized under the laws of the Republic of China, as a business division (the entities may be collectively referred to herein as CVie) focused on development of drug product candidates for cardiovascular diseases, including acute heart failure and hypertension and associated organ dysfunction.

Our four lead development programs are (1) istaroxime for treatment of acute decompensated heart failure (ADHF), (2) AEROSURF® (lucinactant for inhalation) for non-invasive delivery of our lyophilized KL4 surfactant to treat RDS in premature infants, (3) lyophilized KL4 surfactant intratracheal suspension for RDS, and (4) rostafuroxin for genetically associated hypertension.

Table of Contents

The reader is referred to, and encouraged to read in its entirety, Item 1 – Business in our Annual Report on Form 10-K for the year ended December 31, 2018 that we filed with the Securities and Exchange Commission (SEC) on April 16, 2019, as amended by the Form 10-K/A that we filed with the SEC on April 23, 2019 (collectively, 2018 10-K), which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.

Note 2 –

Basis of Presentation

These interim unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US (US GAAP) for interim financial information in accordance with the instructions to Form 10-Q and include accounts of Windtree and its wholly-owned subsidiaries. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, the prior year interim unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation. Operating results for the three months ended March 31, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. There have been no changes to our critical accounting policies since December 31, 2018. The accompanying interim unaudited condensed financial statements should be read in conjunction with annual audited financial statements and related notes as of and for the year ended December 31, 2018 contained in the Company’s 2018 Form 10-K.

Note 3 –

Liquidity Risks and Management’s Plans

As of March 31, 2019, we had cash and cash equivalents of $2.1 million and available-for-sale, marketable securities of $13.5 million, and current liabilities of $17.0 million, including $7.5 million of Loan payable (see, Note 7 - Loan Payable). As of May 10, 2019, we believe that we have sufficient resources (including marketable securities) available to support our development activities, business operations and debt service through October 2019.

Although we believe that the CVie Acquisition and a $39 million private placement financing that closed on the same date (the Private Placement Financing) have improved our financial position and may better position us to raise the capital needed to fund our business plans, we expect to continue to incur significant losses and require significant additional capital to advance our istaroxime and AEROSURF clinical development programs and other activities, support our operations and business development efforts, and satisfy our obligations beyond October 2019, and we do not have sufficient cash and cash equivalents for at least the next year following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

Table of Contents

To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to raise additional capital through a combination of public or private equity offerings and strategic transactions, including but not limited to potential alliances and collaborations focused on various individual markets; however, none of these alternatives are committed at this time. There can be no assurance that we will be able to complete any public or private equity offerings on acceptable terms, or in amounts required to support our operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If none of these alternatives is available, or if available, we are unable to raise sufficient capital through such transactions, we will not have sufficient cash resources and liquidity to fund our business operations for at least the next year following the date that the financial statements are issued. Accordingly, management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through one year after the issuance of the accompanying financial statements.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

As of March 31, 2019, there were 120 million shares of common stock and 5 million shares of preferred stock authorized under our Certificate of Incorporation, and approximately 72.0 million shares of common stock and 5.0 million shares of preferred stock available for issuance and not otherwise reserved.

Note 4 –

Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).

Business Combinations

We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results may differ materially from estimates.

Goodwill and Intangible Assets

We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. The following table represents identifiable intangible assets as of March 31, 2019:

(in thousands)	Estimated Fair Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is not amortized. We perform an annual impairment test for goodwill and evaluate the recoverability whenever events or changes in circumstances indicate that the carrying value of goodwill may not be fully recoverable. In making such assessment, qualitative factors are used to determine whether it is more likely than not that our fair value is less than our carrying value. If the estimated fair value is less than our carrying value, then an impairment loss is recorded.

Table of Contents

Foreign Currency Transactions

The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are not denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other income (expense). Foreign currency transactions resulted in gains of approximately $0.2 million for the three months ended March 31, 2019. There were no foreign currency transaction gains or losses for the three months ended March 31, 2018.

Use of Estimates

The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Marketable Securities

Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) 320, Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in other income (expense) on a specific-identification basis. For the three months ended March 31, 2019, we had $11,000 in realized gains and $40,000 in unrealized gains on marketable securities. There were no realized or unrealized gains or losses on investments for the three months ended March 31, 2018.

We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss, have the intent to sell the investment, or if it is more likely than not that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period.

Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security.

Leases

Effective January 1, 2019, we adopted ASC Topic 842, Leases (ASC 842), using the modified retrospective transition approach and utilizing the effective date as the date of initial application. Consequently, prior period balances and disclosures have not been restated and are presented in accordance with the previous guidance in ASC Topic 840, Leases.

At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than one year are recognized on the balance sheet as operating lease right-of-use assets and current and non-current operating lease liabilities, as applicable. We elected not to recognize on the balance sheet leases with terms of 12 months or less. We typically only include the initial lease term in our assessment of a lease arrangement. Options to extend a lease are not included in our assessment unless there is reasonable certainty that we will renew.

Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received. The interest rate implicit in our leases is typically not readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC 842, we utilized the remaining lease term of our leases in determining the appropriate incremental borrowing rates.

Table of Contents

Restructured Debt Liability – Contingent Milestone Payment

In conjunction with the November 2017 restructuring and retirement of long-term debt (see, Note 8 – Restructured Debt Liability), we established a $15 million long-term liability for contingent AEROSURF regulatory and commercial milestone payments, beginning with the filing for marketing approval in the United States, potentially due under the Exchange and Termination Agreement dated as of October 27, 2017 (Exchange and Termination Agreement), between ourselves and affiliates of Deerfield Management Company L.P. (Deerfield). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are not achieved and the liability is written off as a gain on debt restructuring.

Research and Development

We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic 730, Research and Development.

Net Loss per Common Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of March 31, 2019 and 2018, the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of certain stock options and warrants was 15.2 million and 1.0 million shares, respectively. For the three months ended March 31, 2019 and 2018, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.

We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is not assured.

Recently Adopted Accounting Standards

In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02). ASU 2016-02 establishes ASC 842 which amends ASC 840, Leases, by introducing a lessee model that requires balance sheet recognition for most leases and the disclosure of key information about leasing arrangements. ASC 842 was subsequently amended during 2018. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. We adopted the new standard using the required modified retrospective approach on January 1, 2019 and used the effective date as its date of initial application. Consequently, financial information is not updated and the disclosures required under the new standard are not provided for dates and periods prior to January 1, 2019. Instead, the requirements of ASC 840 are presented for these prior periods.

ASC 842 provides several optional practical expedients in transition. We elected the package of practical expedients which allowed us to not reassess its existing conclusions on lease identification, classification, and initial direct costs. Further, we elected to utilize the short-term lease exemption for all leases with an original term of 12 months or less, for purposes of applying the recognition and measurement requirements of the new standard. We also elected the practical expedient to not separate lease and non-lease components for all our leases.

Table of Contents

The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of $2.2 million and $2.0 million, respectively, related to our operating leases. The adoption of ASC 842 also resulted in the elimination of deferred rent of approximately $72,000 and $139,000 in accrued expenses and other long-term liabilities, respectively, in our condensed consolidated balance sheets. The adoption of the standard did not have a material impact on our condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. Refer to Note 10 – Leases, for our current lease commitments.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The new standard simplifies the subsequent measurement of goodwill by eliminating the second step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted this guidance on January 1, 2019 and will apply it to our annual impairment test, and any interim impairment tests during the year ending December 31, 2019.

Recently Issued Accounting Standards

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic 820. Companies will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy as well as the valuation processes of Level 3 fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. We are currently evaluating the impact that the adoption of ASU 2018-13 will have on our consolidated financial statements.

Note 5 –

License Revenue with Affiliate

	Three Months Ended March 31,
(in thousands)	2019		2018

License revenue with affiliate	$	40	$	204

License revenue with affiliate for the three months ended March 31, 2019 represents revenue from a License Agreement with Lee’s Pharmaceutical (HK) Ltd. (Lee’s (HK)), an affiliate of our largest shareholder, Lee’s Pharmaceutical Holdings Limited (Lee’s), and constitutes a contract with a customer accounted for in accordance with ASC Topic 606.

Note 6 –

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

	●	Level 1 – Quoted prices in active markets for identical assets and liabilities.
	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	March 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	2,053	$	2,053	$	-	$	-
U.S. Treasury notes		13,514		13,514		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	15,738	$	15,738	$	-	$	-

Table of Contents

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	5,234	$	5,234	$	-	$	-
U.S. Treasury notes		19,912		19,912		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	25,317	$	25,317	$	-	$	-

Note 7 –

Loan Payable

In January 2018 and March 2018, LPH Investments Limited (LPH), an affiliate of Lee’s, agreed to lend us $1.5 million and $1.0 million, respectively, to support our AEROSURF development activities and sustain our operations while we sought to identify and advance one or more potential strategic initiatives as defined in the related loan agreements (Funding Event). The loans accrued interest at a rate of 6% per annum and would mature upon the earlier of the closing date of the Funding Event or December 31, 2018. To secure our obligations under these loans, we granted LPH a security interest in substantially all our assets pursuant to the terms of a Security Agreement with LPH dated March 1, 2018 (LPH Security Agreement). Effective December 5, 2018, LPH assigned all outstanding loans to us to LPH II Investment Limited (LPH II). In connection with the Private Placement Financing, we converted $6.0 million of the then outstanding loan payable obligations to LPH II on the same terms as those of the investors in the private placement. Included in the conversion were the $1.5 million and $1.0 million loans.

Assumption of bank debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately $4.5 million in a bank credit facility due in March 2020.

In September 2016, CVie entered into a 12-month revolving credit facility of approximately $2.9 million with O-Bank Co., Ltd. to finance operating activities. The facility was later renewed and increased to approximately $5.8 million in September 2017. The credit facility was guaranteed by Lee’s, which pledged bank deposits in the amount of 110% of the actual borrowing amount. The guaranty was part of the facility; however, we do not have a written commitment from Lee’s to maintain the collateral. Interest, payable in cash on a monthly basis, is determined based on 90-day TAIBOR (the Taipei Interbank Offer Rate) plus 0.91%. The credit facility will expire on September 11, 2019 and matures six months after the expiration date, on March 11, 2020. Although we reached an understanding with Lee’s that it would maintain the bank deposits securing its guaranty obligation under the credit facility, we do not have a written agreement with Lee’s requiring it to do so; therefore, the $4.5 million outstanding under the facility has been classified as a current liability on the condensed consolidated balance sheets.

As of March 31, 2019, the outstanding principal was approximately $4.5 million.

Assumption of Lee’s debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately $3.5 million of debt payable to Lee’s Pharmaceutical International Limited (Lee’s International).

From April 24, 2018 to November 16, 2018, CVie entered into four separate agreements to borrow an aggregate of approximately $3.5 million from Lee’s International. The terms of the loan agreements are identical where the interest, payable in cash upon maturity, is 4% per annum and each of the four separate loans will mature one year from the effective date as follows: $0.5 million in April 2019; $0.3 million in September 2019; $0.2 million in October 2019; and $2.5 million in November 2019.

During the quarter ended March 31, 2019, we made payments of $0.45 million against the April 2018 loan and paid the remaining $50,000 balance plus accrued interest in April 2019. As of March 31, 2019, the outstanding principal of the loans with Lee’s was $3.0 million.

Table of Contents

Note 8 –

Restructured Debt Liability

	March 31,		December 31,
(in thousands)	2019		2018

Restructured debt liability - contingent milestone payments	$	15,000	$	15,000

On November 1, 2017, we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P. (Deerfield Loan) in the aggregate principal amount of $25 million and (ii) warrants to purchase up to 25,000 shares of our common stock at an exercise price of $786.80 per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of $2.5 million, (ii) 71,111 shares of common stock, representing 2% of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to $15 million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a $15 million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (see, Note 4 – Summary of Significant Accounting Policies). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are not achieved and the liability is written off as a gain on debt restructuring.

Note 9 –

Stock Options and Stock-Based Employee Compensation

We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three years. We recognize restricted stock unit awards to employees and non-employee directors based on their fair value on the date of grant. Compensation expense related to restricted stock unit awards is recognized ratably over the vesting period, which typically has been between approximately six to 18 months.

A summary of activity under our long-term incentive plan is presented below:

				Weighted-		Weighted- Average
(in thousands, except for weighted-average data)				Average		Remaining
Stock Options	Shares			Exercise Price		Contractual Term (In Yrs)

Outstanding at January 1, 2019		4,417		$	6.73
Granted		824			4.11
Forfeited or expired		(4	)		576.33
Outstanding at March 31, 2019		5,237		$	5.91		9.7

Vested and exercisable at March 31, 2019		69		$	130.39		6.7

Vested and expected to vest at March 31, 2019		4,942		$	5.89		9.7

Table of Contents

(in thousands, except for weighted-average data)

Restricted Stock Units	Shares			Weighted- Average Grant Date Fair Value

Unvested at January 1, 2019		151		$	4.29
Awarded		249			3.95
Vested		(95	)		3.95
Cancelled		(144	)		4.33
Unvested at March 31, 2019		161		$	4.22

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

	Three Months Ended March 31,
	2019

Weighted average expected volatility		96	%
Weighted average expected term (in years)		6.5
Weighted average risk-free interest rate		2.60	%
Expected dividends		-

The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

	Three Months Ended March 31,
(in thousands)	2019		2018

Research and development	$	489	$	110
General and administrative		1,041		308
Total	$	1,530	$	418

Note 10 –

Leases

Our operating leases consist primarily of facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan.

We maintain our corporate headquarters and operations in Warrington, Pennsylvania, with a remaining non-cancelable term of approximately three years. The facility serves as the main operating facility for drug and device development, regulatory, analytical technical services, research and development, and administration. We also maintain offices in Taipei, Taiwan, the former headquarters of CVie Therapeutics, where we perform certain manufacturing development and preclinical activities related to our cardiovascular drug product candidates.

Throughout the term of our leases, we are responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities.

Table of Contents

The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to our operating leases for the three months ended March 31, 2019:

	Three Months Ended March 31,
(in thousands)	2019

Operating lease cost	$	238
Variable lease cost		7
Total lease cost	$	245

Other Information
Operating cash flows used for operating leases	$	253
Weighted average remaining lease term (in years)		2.9
Weighted average incremental borrowing rate		9.00	%

Future minimum lease payments under our non-cancelable operating leases as of March 31, 2019, are as follows:

	Three Months Ended March 31,
(in thousands)	2019

2019 (excluding the three months ended March 31, 2019)	$	699
2020		666
2021		654
2022		194
2023		28
Thereafter		-
Total lease payments		2,241
Less imputed interest		(260	)
Total operating lease liabilities at March 31, 2019		1,981

The total aggregate base rental payments remaining under the leases as of December 31, 2018 were approximately $2.1 million.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing activities, includes forward-looking statements that involve risks and uncertainties. The reader should review the Forward-Looking Statements section, any risk factors discussed in the Risk Factors Section and elsewhere in this Quarterly Report on Form 10-Q, which are in addition to and supplement the risk factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2018 that we filed with the Securities and Exchange Commission (SEC) on April 16, 2019, as amended by the Form 10-K/A that we filed with the SEC on April 23, 2019 (collectively, 2018 Form 10-K), and our other filings with the SEC, and any amendments thereto, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis or elsewhere in this Quarterly Report on Form 10-Q.

This MD&A is provided as a supplement to the accompanying unaudited Condensed Consolidated Financial Statements (including the notes thereto) to help provide an understanding of our financial condition and changes in our financial condition and our results of operations. This item should be read in connection with our accompanying interim unaudited Condensed Consolidated Financial Statements (including the notes thereto) and the 2018 Form 10-K. Unless otherwise specified, references to Notes in this MD&A shall refer to the Notes to Condensed Consolidated Financial Statements (unaudited) in this Quarterly Report on Form 10-Q.

Table of Contents

OVERVIEW

Heart failure is a chronic, progressive disease resulting from structural or functional cardiac abnormalities and is characterized by inadequate pumping function of the heart that results in fluid accumulation manifesting as pulmonary congestion, peripheral edema and congestion in other parts of the body. Insufficient cardiac output can result in inadequate peripheral perfusion that increases the risk of other organ dysfunction such as renal failure. Heart failure commonly but episodically worsens to a point of decompensation, a condition called ADHF. Istaroxime has a dual mechanism of action referred to as luso-inotropic, that may result in improvement in cardiac function to reduce congestion and edema and preserve other organ function while avoiding the side effects associated with other classes of heart failure therapies. Istaroxime has been evaluated in two phase 2 clinical trials, the results of which suggest that istaroxime may improve cardiovascular physiology as assessed by parameters of pump function, decreases in pulmonary capillary wedge pressure, decreases in heart rate, increases in blood pressure without adverse events such as arrhythmias, cardiac damage (as indicated by elevated troponin values) or adverse impact on kidney function. Based on preclinical and clinical studies performed to date, we believe that istaroxime, if approved, could potentially improve patients’ heart failure symptoms and reduce complications and the length of hospital stays when compared to current therapeutic regimens for ADHF. In 2019, we plan to work with heart failure experts to review the program and engage with the FDA and regulators in the EU to determine next steps in clinical development for this potential novel therapy for ADHF.

AEROSURF (lucinactant for inhalation) is an investigational combination drug/device product that we are developing to improve the management of RDS in premature infants who may not have fully developed natural lung surfactant and may require surfactant therapy to sustain life. Surfactants in the US are animal-derived and must be administered using endotracheal intubation, frequently with mechanical ventilation, invasive procedures that may result in serious respiratory conditions and other complications. AEROSURF is designed to deliver aerosolized KL4 surfactant noninvasively using our proprietary aerosol delivery systems (ADS) technology, without invasive procedures. In 2017, we completed a phase 2b clinical trial, which based on the planned top-line results, did not meet the primary endpoint of reduction in nCPAP failure at 72 hours, due in large part, we believe, to an unexpected rate of treatment interruptions, which occurred in about 24% of active enrollments, predominantly in the 50-minute dose group. We believe the interruptions were primarily related to certain of the prototype phase 2 ADS with specific lots of disposable cartridge filters that had a higher tendency to clog. After excluding patients in the 50-minute dose group whose dose was interrupted, in accordance with the predesignated statistical plan, we observed a meaningful treatment effect in line with our desired targeted outcome. The overall data suggest that the safety and tolerability profile of AEROSURF was generally comparable to the control group. Reported adverse events and serious adverse events were those that are common and expected among premature infants with RDS and comparable to the control group. In 2019, we are planning to initiate an additional AEROSURF clinical bridging study that is designed, among other things, to clinically evaluate the design and performance of our new phase 3 ADS. This trial will not be powered to establish statistical significance but will generate additional higher dose treatment data to augment the higher dose data obtained in the phase 2b clinical trial. We believe that AEROSURF, if approved, has the potential to reduce the number of premature infants who are subjected to invasive surfactant administration, and potentially provide transformative clinical and pharmacoeconomic benefits. The FDA has granted Fast Track designation for our KL4 surfactant (including AEROSURF) to treat RDS.

Table of Contents

We are also assessing potential development pathways to secure marketing approval for lyophilized KL4 surfactant as an intratracheal instillate for the treatment and/or prevention of RDS. Lyophilized KL4 surfactant is the drug product component of AEROSURF and a lyophilized dosage form of a liquid KL4 surfactant that was approved by the FDA in 2012 (SURFAXIN®). We previously discussed with the FDA a potential approach and plan potentially to re-engage with the FDA in the second half of 2019. If we can define an acceptable development plan that is achievable from a cost, timing and resource perspective, we may seek approval to treat premature infants who, because they are unable to breathe on their own or other reason, are not candidates for AEROSURF.

We also believe that our lyophilized KL4 surfactant may potentially support a product pipeline to address a broad range of serious respiratory conditions in children and adults. We are pursuing a number of early exploratory research efforts to identify potential product candidates, including a collaboration with Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, to assess the feasibility of using our ADS potentially to deliver Eleison’s inhaled lipid cisplatin (ILC), and, with support from the National Institutes of Health (NIH), to address respiratory conditions.

Our fourth product candidate is rostafuroxin for the treatment of genetically associated hypertension. Rostafuroxin targets resistant hypertensive patients with a specific genetic profile, which is found in approximately 20% to 25% of the adult hypertensive population. We believe that rostafuroxin may reduce or normalize blood pressure in this genetically identified subset of patients and may reduce the risk of hypertension-related sequelae beyond the level normally associated with the absolute reduction of blood pressure, per se, because the molecular mechanism blocked by rostafuroxin may also be involved in organ damage. CVie Therapeutics completed three clinical trials assessing rostafuroxin, including a phase 2b clinical trial which was conducted in two parts, one in Caucasian patients in Italy and one in Chinese patients in Taiwan. While the blood pressure reduction in Caucasians was notable, there was no blood pressure response in Chinese patients. We are analyzing the results of these studies potentially to understand the reasons for the limited response in Chinese patients. In 2019, we plan to focus on finalizing the drug formulation and defining drug product analytical methods. We then plan to engage in business development activities potentially to out-license rostafuroxin to a larger company that has an interest in and/or operates in the very large and broad antihypertension market.

Business and Program Updates

In addition, on April 24, 2019, our Board of Directors (the Board) adopted a resolution expanding the size of our Board from six to seven and appointed Daniel Geffken to the Board. Mr. Geffken was also appointed Chairman of the Audit Committee of the Board and a member of the Compensation Committee of the Board.

With respect to our AEROSURF® development program, on May 9, 2019, we announced that we had presented a new post-hoc analysis from our phase 2b AEROSURF clinical trial suggesting that AEROSURF may reduce the overall incidence and severity of bronchopulmonary dysplasia (BPD) in premature infants with RDS, regardless of whether the infant was ultimately intubated. The new data were presented in May 2019 at the Pediatric Academic Societies (PAS) Meeting, the leading event for academic pediatrics and child health research.

This Quarterly Report on Form 10-Q includes information concerning our AEROSURF clinical and device development programs. The AEROSURF phase 2b clinical trial has been supported to date, in part, by a $2.6 million Phase IIb award under a Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) under parent award number R44HL107000. In addition, we received funding under a Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) under parent grant number R44AI102308. The content of this Quarterly Report on Form 10-Q is solely our responsibility and does not necessarily represent the official views of the NIH.

Table of Contents

CRITICAL ACCOUNTING POLICIES

There have been no changes to our critical accounting policies since December 31, 2018. For a discussion of our accounting policies, see, Note 4 – Summary of Significant Accounting Policies and, in the Notes to Consolidated Financial Statements (Notes) in our 2018 Form 10-K, Note 5 – Accounting Policies and Recent Accounting Pronouncements. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

RESULTS OF OPERATIONS

Operating Loss and Net Loss

The operating loss for the three months ended March 31, 2019 and 2018 was $6.7 million and $4.8 million, respectively. The increase in operating loss from 2018 to 2019 was due to a $1.7 million increase in operating expenses and a $0.2 million decrease in total revenue.

The net loss for the three months ended March 31, 2019 and 2018 was $6.5 million and $4.5 million, respectively.

License Revenue with Affiliate

	Three Months Ended March 31,
(in thousands)	2019		2018

License revenue with affiliate	$	40	$	204

Research and Development Expenses

Our research and development expenses are charged to operations as incurred and we account for such costs by category rather than by project. As many of our research and development activities likely form the foundation for the potential development of multiple product candidates, including istaroxime, our KL4 surfactant and drug delivery technologies, and rostafuroxin, they are expected to benefit more than a single project. For that reason, we cannot reasonably estimate the costs of our research and development activities on a project-by-project basis. We believe that tracking our expenses by category is a more accurate method of accounting for these activities. Our research and development costs consist primarily of expenses associated with (a) product development and manufacturing, (b) clinical, medical and regulatory operations, and (c) direct preclinical and clinical development programs. We also account for research and development and report annually by major expense category as follows: (i) salaries and benefits, (ii) contracted services, (iii) raw materials, aerosol devices and supplies, (iv) rents and utilities, (v) depreciation, (vi) contract manufacturing, (vii) travel, (viii) stock-based compensation and (ix) other.

Research and development expenses by category for the three months ended March 31, 2019 and 2018 are as follows:

	Three Months Ended March 31,
(in thousands)	2019		2018

Product development and manufacturing	$	993	$	1,591
Clinical, medical and regulatory operations		1,688		1,230
Direct preclinical and clinical programs		661		297
Total research and development expenses	$	3,342	$	3,118

Research and development expenses include non-cash charges associated with stock-based compensation and depreciation of $0.5 and $0.1 million for the three months ended March 31, 2019 and 2018, respectively.

Table of Contents

Product Development and Manufacturing

Product development and manufacturing includes (i) manufacturing operations, both in-house and with contract manufacturing organizations (CMOs), validation activities, quality assurance and analytical chemistry capabilities that support the manufacture of our drug product candidates used in research and development activities, including istaroxime, KL4 surfactant and rostafuroxin, and our medical devices, including our ADS; (ii) design and development activities related to our ADS for use in our AEROSURF clinical development program; and (iii) pharmaceutical and manufacturing development activities, including development of a lyophilized dosage form of our KL4 surfactant and rostafuroxin. These costs include employee expenses, facility-related costs, depreciation, costs of drug substances (including raw materials), supplies, quality control and assurance activities, analytical services, and expert consultants and outside services to support pharmaceutical and device development activities.

Product development and manufacturing expenses decreased $0.6 million for the three months ended March 31, 2019 compared to the same period in 2018 due to reduction of design and development activities on the phase 3 ADS, following completion of the design verification activities in mid-2018.

Clinical, Medical and Regulatory Operations

Clinical, medical and regulatory operations include (i) medical, scientific, preclinical and clinical, regulatory, data management and biostatistics activities in support of our research and development programs; and (ii) medical affairs activities to provide scientific and medical education support for our product candidates under development. These costs include personnel, expert consultants, outside services to support regulatory and data management, symposiums at key medical meetings, facilities-related costs, and other costs for the management of clinical trials.

Clinical, medical and regulatory operations expenses increased $0.5 million for the three months ended March 31, compared to the same period in 2018 due to an increase in non-cash, stock compensation expense as a result of employee stock option grants in the fourth quarter of 2018 and the first quarter of 2019.

Direct Preclinical and Clinical Development Programs

Direct preclinical and clinical development programs include (i) development activities, toxicology studies and other preclinical studies; and (ii) activities associated with conducting clinical trials, including patient enrollment costs, clinical site costs, clinical device and drug supply, and related external costs, such as consultant fees and expenses.

Direct preclinical and clinical development programs expenses increased $0.4 million for the three months ended March 31, 2019 compared to the same period in 2018 due to costs associated with preclinical activities related to potential follow-on product candidates in acute heart failure.

General and Administrative Expenses

	Three Months Ended March 31,
(in thousands)	2019		2018

General and administrative expenses	$	3,355	$	1,926

General and administrative expenses consist of costs for executive management, business development, intellectual property, finance and accounting, legal, human resources, information technology, facility, and other administrative costs.

General and administrative expenses increased $1.4 million for the three months ended March 31, 2019 compared to the same period in 2018 due to an increase in non-cash, stock compensation expense as a result of employee stock option grants in the fourth quarter of 2018 and the first quarter of 2019 and an increase in employee-related incentive bonus accruals.

Table of Contents

Other Income and (Expense)

	Three Months Ended March 31,
(in thousands)	2019			2018

Interest income		60			4
Interest expense		(136	)		(90	)
Other income		196			414
Other income, net	$	120		$	328

The increase in interest income is due to the increase in cash and marketable securities available-for-sale as a result of the Private Placement Financing.

For 2019, interest expense consists of interest expense associated with the collaboration and device development payables and with the loan payable. For 2018, interest expense primarily consists of interest expense associated with amounts due to Battelle Memorial Institute under a 2014 Collaboration Agreement, and device development payables, and interest expense related to $2.5 million in loans payable to LPH.

For 2019, other income primarily consists of $0.2 million in gains on foreign currency translation. For 2018, other income primarily consists of proceeds from the sale of Commonwealth of Pennsylvania research and development tax credits.

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2019, we had cash and cash equivalents of $2.1 million and available-for-sale, marketable securities of $13.5 million, and current liabilities of $17.0 million, including $7.5 million of Loan payable (see, Note 7 – Loan Payable). As of May 10, 2019, we believe that we have sufficient resources (including marketable securities) available to support our development activities, business operations and debt service through October 2019.

Table of Contents

Cash Flows

Cash outflows for the three months ended March 31, 2019, consist of $8.8 million used for ongoing operating activities and $0.6 million used for financing activities, offset by cash inflows for the three months ended March 31, 2019 of $0.4 million for investing activities.

Operating Activities

Net cash used in operating activities for the three months ended March 31, 2019 and 2018 was $8.8 million and $2.5 million, respectively. Net cash used in operating activities is a result of our net losses for the period, adjusted for non-cash items and changes in working capital. The increase in net cash used in operating

activities is due to the payment of CVie Acquisition costs and Private Placement Financing costs and the payment of pre-existing obligations with the proceeds of the Private Placement Financing. The net cash used in operating activities for the three months ended March 31, 2018 reflected our cash conservation efforts during that period.

Investing Activities

Net cash provided by investing activities for the three months ended March 31, 2019 represents $0.5 million related to the sale of marketable securities, partially offset by $0.1 million in purchase of property and equipment.

Financing Activities

Net cash used in financing activities for the three months ended March 31, 2019 was $0.6 million and represents $0.4 million in principal payments on our Loan payable and $0.1 million related to withholding tax payments for net share settlements of restricted stock units.

Net cash provided by financing activities for the three months ended March 31, 2018 was $2.5 million and represents loan proceeds of $1.5 million and $1.0 million related to loan agreements with LPH.

The following sections provide a more detailed discussion of our available financing facilities.

Loan Payable

In January 2018 and March 2018, LPH Investments Limited (LPH), an affiliate of our largest shareholder, Lee’s Pharmaceutical Holdings Limited (Lee’s), agreed to lend us $1.5 million and $1.0 million, respectively, to support our AEROSURF development activities and sustain our operations while we sought to identify and advance one or more potential strategic initiatives as defined in the related loan agreements (Funding Event). The loans accrued interest at a rate of 6% per annum and would mature upon the earlier of the closing date of the Funding Event or December 31, 2018. To secure our obligations under these loans, we granted LPH a security interest in substantially all our assets pursuant to the terms of a Security Agreement with LPH dated March 1, 2018 (LPH Security Agreement). Effective December 5, 2018, LPH assigned all outstanding loans to us to LPH II Investment Limited (LPH II). In connection with the Private Placement Financing, we converted $6.0 million of the then outstanding loan payable obligations to LPH II on the same terms as those of the investors in the private placement. Included in the conversion were the $1.5 million and $1.0 million loans.

Assumption of bank debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately $4.5 million in a bank credit facility due in March 2020.

In September 2016, CVie entered into a 12-month revolving credit facility of approximately $2.9 million with O-Bank Co., Ltd. to finance operating activities. The facility was later renewed and increased to approximately $5.8 million in September 2017. The credit facility was guaranteed by Lee’s, which pledged bank deposits in the amount of 110% of the actual borrowing amount. Interest, payable in cash on a monthly basis, is determined based on 90-day TAIBOR (the Taipei Interbank Offer Rate) plus 0.91%. The credit facility will expire on September 11, 2019 and matures six months after the expiration date, on March 11, 2020. Although we reached an understanding with Lee’s that it would maintain the bank deposits securing its guaranty obligation under the credit facility, we do not have a written agreement with Lee’s requiring it to do so; therefore, the $4.5 million outstanding under the facility has been classified as a current liability on the condensed consolidated balance sheets.

As of March 31, 2019, the outstanding principal was approximately $4.5 million.

Assumption of Lee’s debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately $3.5 million of debt payable to Lee’s Pharmaceutical International Limited (Lee’s International).

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, including our President and Chief Executive Officer (principal executive officer) and our Senior Vice President and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in internal control

There were no changes in our internal control over financial reporting identified in connection with the evaluation described above that occurred during the quarter ended March 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not aware of any pending legal actions that would, if determined adversely to us, have a material adverse effect on our business and operations.

We have from time to time been involved in disputes and proceedings arising in the ordinary course of business, including in connection with the conduct of our clinical trials. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations and financial condition.

Table of Contents

ITEM 1A. RISK FACTORS

Investing in our securities involves risks. In addition to any risks and uncertainties described elsewhere in this Quarterly Report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in Item 1A. Risk Factors in our 2018 Form 10-K. These risks are not the only risks that could materialize. Additional risks and uncertainties not presently known to us or that we currently consider to be immaterial may also impair our business operations and development activities. Should any of the risks and uncertainties described in our 2018 Form 10-K actually materialize, our business, financial condition and/or results of operations could be materially adversely affected, the trading price of our common stock could decline and a stockholder could lose all or part of his or her investment. In particular, the reader’s attention is drawn to the discussion in Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources.

As of May 10, 2019, we believe that we have sufficient capital to fund our research and development programs, support our business operations and satisfy existing obligations on a timely basis through October 2019. If we do not secure additional capital to support our future activities before our existing cash resources are exhausted, we likely will be unable to continue as a going concern.

As of March 31, 2019, we had cash and cash equivalents of $2.1 million and available-for-sale, marketable securities of $13.5 million, and current liabilities of $17.0 million, including $7.5 million of loan payable. Although we believe that the CVie Acquisition and $39 million Private Placement Financing improved our financial position and may better position us to raise the capital needed to fund our business plans, we expect to continue to incur significant losses and require significant additional capital to advance our clinical development programs, support our operations and business development efforts, and satisfy existing obligations. As of May 10, 2019, we believe that we will have sufficient resources (including marketable securities) to support our development activities and business operations through October 2019.

We have not yet established an ongoing source of revenue sufficient to cover our operating costs and allow us to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital, to fund our research and development programs, support our business operations and pay our existing obligations on a timely basis. We plan to seek the additional capital that we require from potential strategic alliances, collaboration arrangements and other similar transactions, and through potential public and private offerings in the equity markets. If none of these alternatives is available, or if available, we are unable to raise sufficient capital through such transactions, we likely will not have sufficient cash resources and liquidity to fund our business operations, which could significantly limit our ability to continue as a going concern. If we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.

Item 6. Exhibits

Exhibits are listed on the Index to Exhibits at the end of this Quarterly Report. The exhibits required by Item 601 of Regulation S-K, listed on such Index in response to this Item, are incorporated herein by reference.

Table of Contents

INDEX TO EXHIBITS

The following exhibits are included with this Quarterly Report on Form 10-Q.

Exhibit No.	Description	Method of Filing

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.	Filed herewith.

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act.	Filed herewith.

32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	Furnished herewith.

101.1	The following condensed consolidated financial statements from the Windtree Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, formatted in Extensive Business Reporting Language (XBRL): (i) Balance Sheets as of March 31, 2019 (unaudited) and December 31, 2018, (ii) Statements of Operations (unaudited) for the three months ended March 31, 2019 and March 31, 2018, (iii) Statements of Comprehensive Loss (unaudited) for the three months ended March 31, 2019 and March 31, 2018, (iv) Statements of Cash Flows (unaudited) for the three months ended March 31, 2019 and March 31, 2018, and (v) Notes to Condensed Consolidated Financial Statements.

101.INS	Instance Document.	Filed herewith.

101.SCH	XBRL Taxonomy Extension Schema Document.	Filed herewith.

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.	Filed herewith.

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.	Filed herewith.

101.LAB	XBRL Taxonomy Extension Label Linkbase Document.	Filed herewith.

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.	Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Windtree Therapeutics, Inc.
		(Registrant)

Date: May 20, 2019		By: /s/ Craig Fraser
		Craig Fraser
		President and Chief Executive Officer


Date: May 20, 2019		By: /s/ John Tattory
		John Tattory
		Senior Vice President and Chief Financial Officer

EX-31.1 2 ex_145163.htm EXHIBIT 31.1 ex_145163.htm

Exhibit 31.1

CERTIFICATIONS

I, Craig Fraser, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Windtree Therapeutics, Inc. (the “Company);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: May 20, 2019	/s/ Craig Fraser
	Craig Fraser
	President and Chief Executive Officer

EX-31.2 3 ex_145164.htm EXHIBIT 31.2 ex_145164.htm

Exhibit 31.2

CERTIFICATIONS

I, John Tattory, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Windtree Therapeutics, Inc. (the “Company);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: May 20, 2019	/s/John Tattory
	John Tattory
	Senior Vice President and Chief Financial Officer

EX-32.1 4 ex_145165.htm EXHIBIT 32.1 ex_145165.htm

Exhibit 32.1

CERTIFICATIONS

Pursuant to 18 U.S.C. § 1350, each of the undersigned officers of Windtree Therapeutics, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 20, 2019

/s/ Craig Fraser
Craig Fraser
President and Chief Executive Officer


/s/ John Tattory
John Tattory
Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to us and will be retained by us and furnished to the SEC or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-101.INS 5 wint-20190331.xml XBRL INSTANCE DOCUMENT false --12-31 Q1 2019 2019-03-31 10-Q 0000946486 32188855 Yes false Non-accelerated Filer WINDTREE THERAPEUTICS INC /DE/ true wint

1417000

3420000

-72000

5247000

6465000

40000

730162000

728783000

55000

151000

418000

1530000

52000

489000

110000

1041000

308000

1530000

418000

111626000

119398000

16069000

25653000

15738000

25317000

13514000

13959000

16265060

4500000

3500000

2053000

11187000

2053000

5234000

19912000

-9134000

-46000

11358000

2040000

2224000

1994000

0.001

120000000

32188929

32133263

32188855

32133189

32000

-6497000

-4512000

158000

198000

40000

204000

6000000

1500000

1000000

0.0091

3500000

500000

300000

200000

2500000

0.06

0.04

15356000

15476000

50000

41000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended<br /> March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">License revenue with affiliate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align: top; width: 7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></div><div style="display: inline; font-weight: bold;"> –</div></div> </td> <td style="vertical-align: top; width: 93%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Stock Options and Stock-Based Employee Compensation</div></div> </td> </tr> </table> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We recognize in our condensed consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> years. We recognize restricted stock unit awards to employees and non-employee directors based on their fair value on the date of grant.  Compensation expense related to restricted stock unit awards is recognized ratably over the vesting period, which typically has been between approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">A summary of activity under our long-term incentive plan is presented below:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average</div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic;">(in thousands, except for weighted-average data)</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><br /> <div style="display: inline; font-weight: bold;">Stock Options</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise<br /> Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual<br /> Term (In Yrs)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding at January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.73</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 45.6%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">824</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited or expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">576.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,237</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.91</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vested and exercisable at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130.39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vested and expected to vest at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,942</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">(in thousands, except for weighted-average data)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Restricted Stock Units</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Grant<br /> Date Fair<br /> Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested at January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 59.6%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">249</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(144</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">161</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months </div></div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Ended<br /> March 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average expected volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividends</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Ended<br /> March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">489</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">110</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,041</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">308</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 59.6%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,530</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">418</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: bottom;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average</div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic;">(in thousands, except for weighted-average data)</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining</div></div></div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><br /> <div style="display: inline; font-weight: bold;">Stock Options</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise<br /> Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual<br /> Term (In Yrs)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding at January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.73</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 45.6%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">824</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited or expired</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">576.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Outstanding at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,237</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.91</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vested and exercisable at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">130.39</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vested and expected to vest at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,942</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.89</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

-0.20

-1.40

-202000

1530000

418000

25000000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align: top; width: 7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></div><div style="display: inline; font-weight: bold;"> –</div></div> </td> <td style="vertical-align: top; width: 93%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Fair Value of Financial Instruments</div></div> </td> </tr> </table> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of inputs, of which the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> are considered observable and the last unobservable, as follows:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <table border="0" cellpadding="0" cellspacing="0" style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;"> <tr> <td style="vertical-align:middle;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> – Quoted prices in active markets for identical assets and liabilities.</div> </td> </tr> <tr> <td style="vertical-align:middle;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> – Inputs other than Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</div> </td> </tr> <tr> <td style="vertical-align:middle;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> </td> <td style="vertical-align:top;width:3.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">●</div> </td> <td style="vertical-align:top;width:93.3%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> – Unobservable inputs that are supported by little or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> market activity and that are significant to the fair value of the assets or liabilities.</div> </td> </tr> </table> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><div style="display: inline; font-style: italic;">Fair Value on a Recurring Basis</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value measurement using</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,053</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,053</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury notes</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificate of deposit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,738</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,738</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" margin: 0pt;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value measurement using</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury notes</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificate of deposit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div>

200000

15682000

-2003000

1635000

-1118000

-266000

24000

-5000

-293000

22340000

54750000

77090000

136000

90000

60000

4000

13514000

245000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Ended<br /> March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating lease cost</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total lease cost</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">245</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Other Information</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating cash flows used for operating leases</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">253</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average incremental borrowing rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Ended<br /> March 31,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019 (excluding the three months ended March 31, 2019)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">699</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">666</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">654</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">194</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total lease payments</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,241</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less imputed interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(260</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 9pt;">Total operating lease liabilities at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

2100000

2241000

28000

194000

654000

666000

699000

260000

48630000

51284000

111626000

119398000

16960000

20633000

2900000

5800000

4500000

7500000

11000

40000

-598000

2500000

425000

-8759000

-2546000

-6537000

-4512000

-6537000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Standards</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update (ASU) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> Leases (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div>). ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> establishes ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> which amends ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases, by introducing a lessee model that requires balance sheet recognition for most leases and the disclosure of key information about leasing arrangements. ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> was subsequently amended during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. We adopted the new standard using the required modified retrospective approach on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and used the effective date as its date of initial application. Consequently, financial information is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> updated and the disclosures required under the new standard are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> provided for dates and periods prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019. </div>Instead, the requirements of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div> are presented for these prior periods.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> provides several optional practical expedients in transition. We elected the package of practical expedients which allowed us to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassess its existing conclusions on lease identification, classification, and initial direct costs. Further, we elected to utilize the short-term lease exemption for all leases with an original term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months or less, for purposes of applying the recognition and measurement requirements of the new standard. We also elected the practical expedient to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> separate lease and non-lease components for all our leases.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million, respectively, related to our operating leases. The adoption of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> also resulted in the elimination of deferred rent of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$72,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$139,000</div> in accrued expenses and other long-term liabilities, respectively, in our condensed consolidated balance sheets. The adoption of the standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. Refer to Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> – Leases, for our current lease commitments.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">04,</div> Intangibles-Goodwill and Other (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>): Simplifying the Test for Goodwill Impairment. The new standard simplifies the subsequent measurement of goodwill by eliminating the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019 </div>with early adoption permitted. We adopted this guidance on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and will apply it to our annual impairment test, and any interim impairment tests during the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Standards</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> Fair Value Measurement (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820</div>): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div>), which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820.</div> Companies will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer be required to disclose the amount of and reasons for transfers between Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> of the fair value hierarchy as well as the valuation processes of Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> is effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019. </div>The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. We are currently evaluating the impact that the adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> will have on our consolidated financial statements.</div></div></div></div>

120000

328000

6697000

5044000

-6657000

-4840000

238000

2000000

1981000

730000

1251000

253000

2200000

1788000

0.09

P2Y328D

40000

-139000

63000

175000

196000

414000

151000

74000

0.001

5000000

502000

507000

1500000

1000000

499000

2500000

826000

802000

11000

2500000

450000

50000

447000

3342000

3118000

171000

-664184000

-657647000

40000

204000

40000

204000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value measurement using</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,053</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,053</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury notes</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,514</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificate of deposit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,738</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,738</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair value measurement using</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">U.S. Treasury notes</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Certificate of deposit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">171</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total Assets</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;">(in thousands, except for weighted-average data)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"> </div></td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;">Restricted Stock Units</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-<br /> Average<br /> Grant<br /> Date Fair<br /> Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested at January 1, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 59.6%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Awarded</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">249</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.95</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(144</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested at March 31, 2019</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">161</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months </div></div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Ended<br /> March 31,</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 81%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average expected volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividends</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

3355000

1926000

P3Y

P180D

P1Y180D

144000

4.33

249000

3.95

151000

161000

4.29

4.22

95000

3.95

0.026

0.96

69000

130.39

4000

576.33

824000

4417000

5237000

6.73

5.91

4942000

5.89

4.11

P6Y182D

P6Y255D

P9Y255D

3000

3227000

3000

3227000

32133000

32189000

3000000

7469000

7974000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div> –</div></div> </td> <td style="vertical-align: top; width: 93%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</div></div> </td> </tr> </table> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The consolidated financial statements are prepared in accordance with accounting principles generally accepted in the US (US GAAP) and include accounts of Windtree Therapeutics, Inc. and its wholly-owned subsidiaries, CVie Investments, CVie Therapeutics, and a presently inactive subsidiary, Discovery Laboratories, Inc. (formerly known as Acute Therapeutics, Inc.).</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Business Combinations</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We follow the acquisition method for an acquisition of a business where the purchase price is allocated to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition. The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimate of fair value is based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and as such, actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>differ materially from estimates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Goodwill and Intangible Assets</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We record acquired identified intangibles, which includes intangible assets (such as goodwill and other intangibles), based on estimated fair value. The acquired in-process research and development (IPR&D) assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be impaired. The following table represents identifiable intangible assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019:</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"> </div> <div> <table style="margin-right: 10%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 83%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Estimated Fair </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Istaroxime drug candidate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,340</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Rostafuroxin drug candidate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">54,750</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 18pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">77,090</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> amortized. We perform an annual impairment test for goodwill and evaluate the recoverability whenever events or changes in circumstances indicate that the carrying value of goodwill <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be fully recoverable. In making such assessment, qualitative factors are used to determine whether it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that our fair value is less than our carrying value. If the estimated fair value is less than our carrying value, then an impairment loss is recorded.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Foreign Currency Transactions</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other income (expense). Foreign currency transactions resulted in gains of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.2</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> foreign currency transaction gains or losses for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The preparation of financial statements, in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Marketable Securities</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Marketable securities consist of investments in US Treasury securities. Management determines the appropriate classification of these securities at the time they are acquired and evaluates the appropriateness of such classifications at each balance sheet date. We classify investments as available-for-sale pursuant to Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">320,</div> Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in other income (expense) on a specific-identification basis. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>we had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11,000</div> in realized gains and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$40,000</div> in unrealized gains on marketable securities. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> realized or unrealized gains or losses on investments for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss, have the intent to sell the investment, or if it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Available-for-sale marketable securities are classified as marketable securities, current or marketable securities, non-current depending on the contractual maturity date of the individual available-for-sale security.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Leases</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019, </div>we adopted ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,</div> Leases (ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>), using the modified retrospective transition approach and utilizing the effective date as the date of initial application.  Consequently, prior period balances and disclosures have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been restated and are presented in accordance with the previous guidance in ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease based on the unique facts and circumstances present in the arrangement. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Most leases with a term greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are recognized on the balance sheet as operating lease right-of-use assets and current and non-current operating lease liabilities, as applicable. We elected <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to recognize on the balance sheet leases with terms of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months or less. We typically only include the initial lease term in our assessment of a lease arrangement. Options to extend a lease are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in our assessment unless there is reasonable certainty that we will renew. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Operating lease liabilities and their corresponding operating lease right-of-use assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the right-of-use asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required for items such as incentives received. The interest rate implicit in our leases is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842,</div> we utilized the remaining lease term of our leases in determining the appropriate incremental borrowing rates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Restructured Debt Liability – Contingent Milestone Payment</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017 </div>restructuring and retirement of long-term debt (s<div style="display: inline; font-style: italic;">ee,</div> Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> – Restructured Debt Liability), we established a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15</div> million long-term liability for contingent AEROSURF regulatory and commercial milestone payments, beginning with the filing for marketing approval in the United States, potentially due under the Exchange and Termination Agreement dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 27, 2017 (</div>Exchange and Termination Agreement), between ourselves and affiliates of Deerfield Management Company L.P. (Deerfield). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> achieved and the liability is written off as a gain on debt restructuring.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Research and Development</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We account for research and development expense by the following categories: (a) product development and manufacturing, (b) clinical medical and regulatory operations, and (c) direct preclinical and clinical development programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred in accordance with ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">730,</div> Research and Development.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Net Loss per Common Share</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of certain stock options and warrants was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div> million shares, respectively. For the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We account for income taxes in accordance with ASC Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">740,</div> Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We use a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Because we have never realized a profit, management has fully reserved the net deferred tax asset since realization is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> assured.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Standards</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued Accounting Standards Update (ASU) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> Leases (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div>). ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> establishes ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> which amends ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840,</div> Leases, by introducing a lessee model that requires balance sheet recognition for most leases and the disclosure of key information about leasing arrangements. ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> was subsequently amended during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. We adopted the new standard using the required modified retrospective approach on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and used the effective date as its date of initial application. Consequently, financial information is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> updated and the disclosures required under the new standard are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> provided for dates and periods prior to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019. </div>Instead, the requirements of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div> are presented for these prior periods.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> provides several optional practical expedients in transition. We elected the package of practical expedients which allowed us to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> reassess its existing conclusions on lease identification, classification, and initial direct costs. Further, we elected to utilize the short-term lease exemption for all leases with an original term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months or less, for purposes of applying the recognition and measurement requirements of the new standard. We also elected the practical expedient to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> separate lease and non-lease components for all our leases.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million, respectively, related to our operating leases. The adoption of ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div> also resulted in the elimination of deferred rent of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$72,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$139,000</div> in accrued expenses and other long-term liabilities, respectively, in our condensed consolidated balance sheets. The adoption of the standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. Refer to Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> – Leases, for our current lease commitments.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">04,</div> Intangibles-Goodwill and Other (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>): Simplifying the Test for Goodwill Impairment. The new standard simplifies the subsequent measurement of goodwill by eliminating the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019 </div>with early adoption permitted. We adopted this guidance on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>and will apply it to our annual impairment test, and any interim impairment tests during the year ending <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2019.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Standards</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> Fair Value Measurement (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820</div>): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div>), which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">820.</div> Companies will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer be required to disclose the amount of and reasons for transfers between Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> and Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> of the fair value hierarchy as well as the valuation processes of Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> fair value measurements. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> is effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019. </div>The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. We are currently evaluating the impact that the adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div> will have on our consolidated financial statements.</div></div>

56000

62996000

68114000

3000

616245000

-637114000

-3054000

-23920000

3000

616611000

-641626000

-3054000

-28066000

32000

728783000

-657647000

-3054000

32000

730162000

-664184000

40000

-3054000

3054000

7000

32142000

3227000

0.3512 786.80 25000 1939000 2576000 72000000 -692000 49000 -214000 15000000 15000000 15000000 15000000 15000000 15000000 1.1 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style=";text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="vertical-align: top; width: 7%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note </div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></div><div style="display: inline; font-weight: bold;"> –</div></div> </td> <td style="vertical-align: top; width: 93%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Liquidity Risks and Management’s Plans</div><div style="display: inline; font-weight: bold;"> </div></div> </td> </tr> </table> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>we had cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.1</div> million and available-for-sale, marketable securities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13.5</div> million, and current liabilities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$17.0</div> million, including <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$7.5</div> million of Loan payable (<div style="display: inline; font-style: italic;">see</div>, Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div> - Loan Payable).  As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 10, 2019, </div>we believe that we have sufficient resources (including marketable securities) available to support our development activities, business operations and debt service through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Although we believe that the CVie Acquisition and a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39</div> million private placement financing that closed on the same date (the Private Placement Financing) have improved our financial position and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>better position us to raise the capital needed to fund our business plans, we expect to continue to incur significant losses and require significant additional capital to advance our istaroxime and AEROSURF clinical development programs and other activities, support our operations and business development efforts, and satisfy our obligations beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2019, </div>and we do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have sufficient cash and cash equivalents for at least the next year following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern within <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the date that the financial statements are issued.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, management plans to raise additional capital through a combination of public or private equity offerings and strategic transactions, including but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to potential alliances and collaborations focused on various individual markets; however, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of these alternatives are committed at this time.  There can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance that we will be able to complete any public or private equity offerings on acceptable terms, or in amounts required to support our operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">none</div> of these alternatives is available, or if available, we are unable to raise sufficient capital through such transactions, we will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have sufficient cash resources and liquidity to fund our business operations for at least the next year following the date that the financial statements are issued. Accordingly, management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year after the issuance of the accompanying financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div> million shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div> million shares of preferred stock authorized under our Certificate of Incorporation, and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72.0</div> million shares of common stock and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.0</div> million shares of preferred stock available for issuance and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> otherwise reserved.</div></div> 15200000 1000000 192000 5000000 39000000 171000 171000 171000 171000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Restructured Debt Liability – Contingent Milestone Payment</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In conjunction with the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017 </div>restructuring and retirement of long-term debt (s<div style="display: inline; font-style: italic;">ee,</div> Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div> – Restructured Debt Liability), we established a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15</div> million long-term liability for contingent AEROSURF regulatory and commercial milestone payments, beginning with the filing for marketing approval in the United States, potentially due under the Exchange and Termination Agreement dated as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 27, 2017 (</div>Exchange and Termination Agreement), between ourselves and affiliates of Deerfield Management Company L.P. (Deerfield). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> achieved and the liability is written off as a gain on debt restructuring.</div></div></div></div> 71111 0.02 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares iso4217:TWD 0000946486 wint:DeerfieldManagementLPMember wint:DeerfieldLoanMember wint:ExchangeAndTerminationAgreementMember 2017-11-01 2017-11-01 0000946486 wint:LPHMember 2018-01-01 2018-01-31 0000946486 2018-01-01 2018-03-31 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-03-31 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-03-31 0000946486 us-gaap:LicenseMember 2018-01-01 2018-03-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000946486 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000946486 us-gaap:PreferredStockMember 2018-01-01 2018-03-31 0000946486 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000946486 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000946486 wint:LPHMember 2018-03-01 2018-03-31 0000946486 2018-12-21 2018-12-21 0000946486 wint:CvieInvestmentMember 2018-12-21 2018-12-21 0000946486 us-gaap:RevolvingCreditFacilityMember wint:OBankCoLtdMember wint:TaipeiInterbankOfferRateTaAIBORMember 2018-12-21 2018-12-21 0000946486 wint:LoanPayableObligationConvertedToLphIIMember 2018-12-21 2018-12-21 0000946486 wint:LoanPayableObligationConvertedToLphIIMember wint:DebtIssuedOnJanuary2018Member wint:LPHMember 2018-12-21 2018-12-21 0000946486 wint:LoanPayableObligationConvertedToLphIIMember wint:DebtIssuedOnMarch2018Member wint:LPHMember 2018-12-21 2018-12-21 0000946486 2019-01-01 2019-03-31 0000946486 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0000946486 us-gaap:RestrictedStockUnitsRSUMember wint:The2011LongtermIncentivePlanMember srt:MaximumMember 2019-01-01 2019-03-31 0000946486 us-gaap:RestrictedStockUnitsRSUMember wint:The2011LongtermIncentivePlanMember srt:MinimumMember 2019-01-01 2019-03-31 0000946486 wint:StockBasedAwardsMember wint:The2011LongtermIncentivePlanMember 2019-01-01 2019-03-31 0000946486 wint:DebtPayableToLeesInternationalMember 2019-01-01 2019-03-31 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0000946486 us-gaap:LicenseMember 2019-01-01 2019-03-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000946486 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000946486 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0000946486 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000946486 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000946486 wint:DebtPayableToLeesInternationalMember us-gaap:SubsequentEventMember 2019-04-01 2019-04-30 0000946486 us-gaap:RevolvingCreditFacilityMember wint:CVieInvestmentsMember wint:OBankCoLtdMember 2016-09-30 0000946486 wint:DeerfieldManagementLPMember wint:DeerfieldLoanMember wint:ExchangeAndTerminationAgreementMember 2017-11-01 0000946486 wint:DeerfieldManagementLPMember wint:DeerfieldLoanMember wint:ExchangeAndTerminationAgreementMember 2017-11-01 0000946486 2017-12-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000946486 us-gaap:CommonStockMember 2017-12-31 0000946486 us-gaap:PreferredStockMember 2017-12-31 0000946486 us-gaap:RetainedEarningsMember 2017-12-31 0000946486 us-gaap:TreasuryStockMember 2017-12-31 0000946486 2018-03-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000946486 us-gaap:CommonStockMember 2018-03-31 0000946486 us-gaap:PreferredStockMember 2018-03-31 0000946486 us-gaap:RetainedEarningsMember 2018-03-31 0000946486 us-gaap:TreasuryStockMember 2018-03-31 0000946486 wint:DebtPayableToLeesInternationalMember 2018-11-16 0000946486 wint:DebtPayableToLeesInternationalMember wint:DebtMaturingApril2019Member 2018-11-16 0000946486 wint:DebtPayableToLeesInternationalMember wint:DebtMaturingNovember2019Member 2018-11-16 0000946486 wint:DebtPayableToLeesInternationalMember wint:DebtMaturingOctober2019Member 2018-11-16 0000946486 wint:DebtPayableToLeesInternationalMember wint:DebtMaturingSeptember2019Member 2018-11-16 0000946486 2018-12-21 0000946486 wint:CVieInvestmentsMember us-gaap:RevolvingCreditFacilityMember wint:OBankCoLtdMember 2018-12-21 0000946486 wint:CVieInvestmentsMember wint:DebtPayableToLeesInternationalMember 2018-12-21 0000946486 us-gaap:RevolvingCreditFacilityMember wint:OBankCoLtdMember 2018-12-21 0000946486 2018-12-31 0000946486 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2018-12-31 0000946486 wint:LPHMember 2018-12-31 0000946486 wint:DeerfieldLoanMember 2018-12-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000946486 us-gaap:CommonStockMember 2018-12-31 0000946486 us-gaap:PreferredStockMember 2018-12-31 0000946486 us-gaap:RetainedEarningsMember 2018-12-31 0000946486 us-gaap:TreasuryStockMember 2018-12-31 0000946486 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000946486 2019-03-31 0000946486 us-gaap:RestrictedStockUnitsRSUMember 2019-03-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:RevolvingCreditFacilityMember wint:OBankCoLtdMember 2019-03-31 0000946486 wint:DebtPayableToLeesInternationalMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember 2019-03-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2019-03-31 0000946486 wint:IstaroximeDrugCandidateMember 2019-03-31 0000946486 wint:RostafuroxinDrugCandidateMember 2019-03-31 0000946486 wint:DeerfieldLoanMember 2019-03-31 0000946486 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000946486 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000946486 us-gaap:CommonStockMember 2019-03-31 0000946486 us-gaap:PreferredStockMember 2019-03-31 0000946486 us-gaap:RetainedEarningsMember 2019-03-31 0000946486 us-gaap:TreasuryStockMember 2019-03-31 0000946486 2019-05-10

EX-101.SCH 6 wint-20190331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - The Company and Description of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Liquidity Risks and Management's Plans link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - License Revenue with Affiliate link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Fair Value of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Loan Payable link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Restructured Debt Liability link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 5 - License Revenue with Affiliate (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 6 - Fair Value of Financial Instruments (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 8 - Restructured Debt Liability (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 1 - The Company and Description of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Liquidity Risks and Management's Plans (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 7 - Loan Payable (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 8 - Restructured Debt Liability (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 8 - Restructured Debt Liability - Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 10 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 10 - Leases - Lease Costs (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 10 - Leases - Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 wint-20190331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 wint-20190331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 wint-20190331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Expected dividends Note To Financial Statement Details Textual Significant Accounting Policies Note 4 - Summary of Significant Accounting Policies 2020 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Note 5 - License Revenue with Affiliate us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Weighted average risk-free interest rate Note 6 - Fair Value of Financial Instruments Note 8 - Restructured Debt Liability Note 9 - Stock Options and Stock-based Employee Compensation Note 10 - Leases us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate Weighted average expected volatility Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) Collaboration and device development payable Represents the increase (decrease) during the reporting period of the balance of the Collaboration Payable pursuant to the collaboration agreement with Battelle. Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) Collaboration and device development payable, net Represents the current amount due to Battelle as of the reporting date pursuant to the collaboration agreement related to the development of a new version of the company's ADS. Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) Unrealized gain on marketable securities Unrealized gain on marketable securities Note 8 - Restructured Debt Liability - Long-term Debt (Details) Foreign Currency Transactions and Translations Policy [Policy Text Block] Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) us-gaap_LiabilitiesCurrent Liabilities, Current, Total Total current liabilities Lessee, Leases [Policy Text Block] Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details) 2019 (excluding the three months ended March 31, 2019) us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) Note 10 - Leases - Lease Costs (Details) Business Combinations Policy [Policy Text Block] Note 10 - Leases - Future Minimum Lease Payments (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Weighted average expected term (Year) Notes To Financial Statements Earnings Per Share, Policy [Policy Text Block] Notes To Financial Statements [Abstract] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Debt Conversion Description [Axis] Amortization of debt discount us-gaap_AdjustmentForAmortization Total revenues Debt Conversion, Name [Domain] CVie Investments [Member] Related to CVie Investments. Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Expenses: Income Tax, Policy [Policy Text Block] us-gaap_AssetsFairValueDisclosure Total Assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Awarded (in dollars per share) Proceeds from sale of marketable securities us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Vested (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Cancelled (in dollars per share) CVie Investment [Member] Represents CVie Investment. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, Beginning Balance (in dollars per share) Unvested, Ending Balance (in dollars per share) US Treasury Securities [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Cancelled (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Unvested, Beginning Balance (in shares) Unvested, Ending Balance (in shares) Research and Development Expense, Policy [Policy Text Block] Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Depreciation us-gaap_Depreciation us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Awarded (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested (in shares) us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Withholding tax payments related to net share settlements of restricted stock units (in shares) Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year) Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Other comprehensive income: Vested and expected to vest (in shares) us-gaap_LoansPayableCurrent Loans Payable, Current, Total Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) Taipei Interbank Offer Rate (TAIBOR) [Member] Related to the Taipei Interbank Offer Rate (TAIBOR). us-gaap_AssetsCurrent Total current assets us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) wint_LineOfCreditFacilityPercentOfPledgedDepositsRequired Line of Credit Facility, Percent of Pledged Deposits Required The percentage amount of pledged deposits required to be held against borrowings under the line of credit facility. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Weighted Average Remaining Contractual Life, Vested and Exercisable (Year) us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash and cash equivalents us-gaap_InvestmentsFairValueDisclosure Cash and cash equivalents Debt Maturing September 2019 [Member] Related to debt maturing September 2019. us-gaap_RealizedInvestmentGainsLosses Realized gain on investments Debt Maturing April 2019 [Member] Related to debt maturing April 2019. Debt Payable to Lee's International [Member] Related to debt payable to Lee's International. O-Bank Co., Ltd. [Member] Related to O-Bank Co., Ltd. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Shares Vested and Exercisable (in shares) Istaroxime Drug Candidate [Member] Related to Istaroxime drug candidate. us-gaap_LinesOfCreditCurrent Line of Credit, Current us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Weighted Average Remaining Contractual Life, Outstanding (Year) Debt Maturing November 2019 [Member] Related to debt maturing November 2019. Debt Maturing October 2019 [Member] Related to debt maturing October 2019. Treasury stock, shares (in shares) Rostafuroxin Drug Candidate [Member] Related to Rostafuroxin drug candidate. Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018; 32,188,929 and 32,133,263 shares issued at March 31, 2019 and December 31, 2018, respectively; 32,188,855 and 32,133,189 shares outstanding at March 31, 2019 and December 31, 2018, respectively Financial Instruments [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Deferred revenue us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) Financial Instrument [Axis] Certificates of Deposit [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Weighted Average Exercise Price, Granted (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Accrued Liabilities, Current, Total Statistical Measurement [Domain] Operating cash flows used for operating leases Maximum [Member] Minimum [Member] Lessee, Operating Leases [Text Block] Accounts payable Revolving Credit Facility [Member] Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Shares Outstanding, Beginning Balance (in shares) Shares Outstanding, Ending Balance (in shares) Product and Service [Domain] Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Shares Forfeited or Expired (in shares) Credit Facility [Axis] Credit Facility [Domain] Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2019 and December 31, 2018 Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Goodwill and Intangible Assets, Policy [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, par value (in dollars per share) Indefinite-lived Intangible Assets [Axis] License revenue with affiliate Indefinite-lived Intangible Assets, Major Class Name [Domain] Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax, Total Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Fair Value Hierarchy and NAV [Axis] Current Liabilities: Weighted average number of common shares outstanding us-gaap_Assets Total assets Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Plan Name [Axis] Plan Name [Domain] Cash flows from operating activities: Statement [Line Items] Liquidity Disclosures [Text Block] Disclosure of historical and expected sources of liquidity, available cash and cash equivalents as of the balance sheet date, and management's plans to maintain sufficient working capital through one or more of the following, if available: public and private securities offerings, equity financing facilities, capital equipment and debt facilities, and strategic alliances, as well as sales revenue from products approved for marketing, if and when approved. Additional paid-in capital Deerfield Loan [Member] Represents the long-term debt under a secure loan - "Deerfield Loan." Revenues: Share-based Payment Arrangement [Text Block] Deerfield Management, L.P. [Member] Represents the affiliates of Deerfield Management, L.P. Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] AOCI Attributable to Parent [Member] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Withholding tax payments related to net share settlements of restricted stock units Stockholders' Equity: Available-for-sale marketable securities Debt Securities, Available-for-sale, Current, Total us-gaap_NonoperatingIncomeExpense Other income / (expense), net Award Type [Domain] Other income wint_CommonStockCapitalSharesAvailableForIssuance Common Stock, Capital Shares Available for Issuance Aggregate number of common shares available for issuance and not otherwise reserved. The 2011 Long-term Incentive Plan [Member] Represents the 2011 Long-Term Incentive Plan. Current Assets: Fair Value Disclosures [Text Block] wint_PreferredStockCapitalSharesAvailableForIssuance Preferred Stock, Capital Shares Available for Issuance Aggregate number of preferred shares available for issuance and not otherwise reserved. Award Type [Axis] Net loss Net loss us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, cash equivalents and restricted cash - beginning of year Cash, cash equivalents and restricted cash - end of year License [Member] Interest income Restricted Stock Units (RSUs) [Member] us-gaap_Liabilities Total liabilities us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash (used in) / provided by financing activities Amortization of operating lease right-of-use assets Amount of amortization expense attributable to right-of-use asset from operating lease. us-gaap_OperatingIncomeLoss Operating loss us-gaap_ContractWithCustomerLiabilityRevenueRecognized Recognition of deferred revenue us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities Other income / (expense): Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash provided by investing activities Effect of exchange rate changes on cash and cash equivalents us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net decrease in cash and cash equivalents Counterparty Name [Axis] Counterparty Name [Domain] wint_NumberOfSharesOfCommonStockPotentiallyIssuableUponTheExerciseOfStockOptionsAndWarrants Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants Represents number of shares of common stock potentially issuable exercise of certain stock options and warrants during the period. Indefinite intangible asset Property and equipment, net Goodwill Accounting Standards Update 2016-02 [Member] Marketable Securities, Policy [Policy Text Block] Type of Adoption [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment for taxes related to net share settlements of restricted stock units Operating lease liabilities The increase (decrease) during the reporting period in the operating lease liability. EX-101.PRE 10 wint-20190331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2019	May 10, 2019
Document Information [Line Items]
Entity Registrant Name	WINDTREE THERAPEUTICS INC /DE/
Entity Central Index Key	0000946486
Trading Symbol	wint
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		32,188,855
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 2,053	$ 11,187
Available-for-sale marketable securities	13,514	13,959
Prepaid expenses and other current assets	502	507
Total current assets	16,069	25,653
Property and equipment, net	826	802
Restricted cash	171	171
Operating lease right-of-use assets	1,788
Indefinite intangible asset	77,090	77,090
Goodwill	15,682	15,682
Total assets	111,626	119,398
Current Liabilities:
Accounts payable	1,417	3,420
Collaboration and device development payable, net	1,939	2,576
Accrued Liabilities, Current, Total	5,247	6,465
Operating lease liabilities - current portion	730
Deferred revenue	158	198
Loan payable	7,469	7,974
Total current liabilities	16,960	20,633
Operating lease liabilities - non-current portion	1,251
Restructured debt liability - contingent milestone payments	15,000	15,000
Deferred tax liabilities	15,356	15,476
Other liabilities	63	175
Total liabilities	48,630	51,284
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2019 and December 31, 2018	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018; 32,188,929 and 32,133,263 shares issued at March 31, 2019 and December 31, 2018, respectively; 32,188,855 and 32,133,189 shares outstanding at March 31, 2019 and December 31, 2018, respectively	32	32
Additional paid-in capital	730,162	728,783
Accumulated deficit	(664,184)	(657,647)
Accumulated other comprehensive income	40	0
Treasury stock (at cost); 74 shares	(3,054)	(3,054)
Total stockholders' equity	62,996	68,114
Total liabilities & stockholders' equity	$ 111,626	$ 119,398

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,188,929	32,133,263
Common stock, shares outstanding (in shares)	32,188,855	32,133,189
Treasury stock, shares (in shares)	74	74

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenues:
Total revenues	$ 40	$ 204
Expenses:
Research and development	3,342	3,118
General and administrative	3,355	1,926
Total operating expenses	6,697	5,044
Operating loss	(6,657)	(4,840)
Other income / (expense):
Interest income	60	4
Interest expense	(136)	(90)
Other income	196	414
Other income / (expense), net	120	328
Net loss	$ (6,537)	$ (4,512)
Net loss per common share
Basic and diluted (in dollars per share)	$ (0.20)	$ (1.40)
Weighted average number of common shares outstanding
Basic and diluted (in shares)	32,142	3,227
License [Member]
Revenues:
License revenue with affiliate	$ 40	$ 204

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Net loss	$ (6,537)	$ (4,512)
Other comprehensive income:
Unrealized gain on marketable securities	40
Comprehensive loss	$ (6,497)	$ (4,512)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017	3	3,227
Balance at Dec. 31, 2017		$ 3	$ 616,245	$ (637,114)		$ (3,054)	$ (23,920)
Net loss				(4,512)			(4,512)
Share Purchase Agreement, April 2018			(52)				(52)
Stock-based compensation expense			418				418
Unrealized gain on marketable securities
Balance (in shares) at Mar. 31, 2018	3	3,227
Balance at Mar. 31, 2018		$ 3	616,611	(641,626)		$ (3,054)	(28,066)
Balance (in shares) at Dec. 31, 2018		32,133
Balance at Dec. 31, 2018		$ 32	728,783	(657,647)		$ (3,054)	68,114
Net loss				(6,537)			(6,537)
Stock-based compensation expense			1,530				1,530
Vesting of restricted stock units (in shares)		56
Vesting of restricted stock units
Withholding tax payments related to net share settlements of restricted stock units (in shares)
Withholding tax payments related to net share settlements of restricted stock units			(151)				(151)
Unrealized gain on marketable securities					40		40
Balance (in shares) at Mar. 31, 2019		32,189
Balance at Mar. 31, 2019		$ 32	$ 730,162	$ (664,184)	$ 40	$ (3,054)	$ 62,996

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (6,537)	$ (4,512)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of deferred revenue	(40)	(204)
Depreciation	50	41
Amortization of operating lease right-of-use assets	192
Amortization of debt discount	55
Stock-based compensation	1,530	418
Realized gain on investments	(11)
Changes in:
Prepaid expenses and other current assets	5	293
Accounts payable	(2,003)	1,635
Collaboration and device development payable	(692)	49
Accrued expenses	(1,118)	(266)
Operating lease liabilities	(214)
Other liabilities	24
Net cash used in operating activities	(8,759)	(2,546)
Cash flows from investing activities:
Purchase of property and equipment	(74)
Proceeds from sale of marketable securities	499
Net cash provided by investing activities	425
Cash flows from financing activities:
Proceeds from loan payable, net of expenses		2,500
Principle payments on loan payable	(447)
Payment for taxes related to net share settlements of restricted stock units	(151)
Net cash (used in) / provided by financing activities	(598)	2,500
Effect of exchange rate changes on cash and cash equivalents	(202)
Net decrease in cash and cash equivalents	(9,134)	(46)
Cash, cash equivalents and restricted cash - beginning of year	11,358	2,040
Cash, cash equivalents and restricted cash - end of year	$ 2,224	$ 1,994

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - The Company and Description of Business

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note

–

The Company and Description of Business

KL4

surfactant technology and aerosol delivery system (ADS) technology for the treatment and/or prevention of respiratory distress syndrome (RDS) in premature infants. On

December 21, 2018,

we entered into an Agreement and Plan of Merger (the CVie Acquisition) with CVie Investments Limited (CVie Investments), an exempted company with limited liability incorporated under the laws of the Cayman Islands, pursuant to which we issued shares of our common stock, par value

$0.001

per share (common stock), to CVie Investments’ former shareholders, at an exchange ratio of

0.3512

share of common stock for each share of CVie Investments outstanding prior to the merger, resulting in the issuance of

16,265,060

shares of common stock in exchange for the outstanding shares of CVie Investments. Since the CVie Acquisition, which closed on

December 21, 2018,

we have operated CVie Investments, and its wholly-owned subsidiary, CVie Therapeutics Limited (CVie Therapeutics), a Taiwan corporation organized under the laws of the Republic of China, as a business division (the entities

may

be collectively referred to herein as CVie) focused on development of drug product candidates for cardiovascular diseases, including acute heart failure and hypertension and associated organ dysfunction.

Our

four

lead development programs are (

) istaroxime for treatment of acute decompensated heart failure (ADHF), (

) AEROSURF® (lucinactant for inhalation) for non-invasive delivery of our lyophilized

KL4

surfactant to treat RDS in premature infants, (

) lyophilized

KL4

surfactant intratracheal suspension for RDS, and (

) rostafuroxin for genetically associated hypertension.

The reader is referred to, and encouraged to read in its entirety, Item

– Business in our Annual Report on Form

-K for the year ended

December 31, 2018

that we filed with the Securities and Exchange Commission (SEC) on

April 16, 2019,

as amended by the Form

-K/A that we filed with the SEC on

April 23, 2019 (

collectively,

2018

-K), which contains a discussion of our business and business plans, as well as information concerning our proprietary technologies and our current and planned development programs.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Basis of Accounting [Text Block]

Note

–

Basis of Presentation

-Q and include accounts of Windtree and its wholly-owned subsidiaries. Accordingly, they do

not

include all of the information and footnotes required by US GAAP for complete consolidated financial statements. Intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. When necessary, the prior year interim unaudited condensed consolidated financial statements have been reclassified to conform to the current year presentation. Operating results for the

three

months ended

March 31, 2019

are

not

necessarily indicative of the results that

may

be expected for the year ending

December

31,

2019.

There have been

changes to our critical accounting policies since

December 31, 2018.

The accompanying interim unaudited condensed financial statements should be read in conjunction with annual audited financial statements and related notes as of and for the year ended

December 31, 2018

contained in the Company’s

2018

Form

-K.

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Liquidity Risks and Management's Plans

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Liquidity Disclosures [Text Block]

Note

–

Liquidity Risks and Management’s Plans

As of

March 31, 2019,

we had cash and cash equivalents of

$2.1

million and available-for-sale, marketable securities of

$13.5

million, and current liabilities of

$17.0

million, including

$7.5

million of Loan payable (

see

, Note

- Loan Payable). As of

May 10, 2019,

we believe that we have sufficient resources (including marketable securities) available to support our development activities, business operations and debt service through

October

2019.

Although we believe that the CVie Acquisition and a

$39

million private placement financing that closed on the same date (the Private Placement Financing) have improved our financial position and

may

better position us to raise the capital needed to fund our business plans, we expect to continue to incur significant losses and require significant additional capital to advance our istaroxime and AEROSURF clinical development programs and other activities, support our operations and business development efforts, and satisfy our obligations beyond

October 2019,

and we do

not

have sufficient cash and cash equivalents for at least the next year following the date that the financial statements are issued. These conditions raise substantial doubt about our ability to continue as a going concern within

one

year after the date that the financial statements are issued.

not

limited to potential alliances and collaborations focused on various individual markets; however,

none

of these alternatives are committed at this time. There can be

assurance that we will be able to complete any public or private equity offerings on acceptable terms, or in amounts required to support our operations, if at all, or identify and enter into any strategic transactions that will provide the capital that we will require. If

none

of these alternatives is available, or if available, we are unable to raise sufficient capital through such transactions, we will

not

have sufficient cash resources and liquidity to fund our business operations for at least the next year following the date that the financial statements are issued. Accordingly, management has concluded that substantial doubt exists with respect to our ability to continue as a going concern through

one

year after the issuance of the accompanying financial statements.

not

include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

As of

March 31, 2019,

there were

120

million shares of common stock and

million shares of preferred stock authorized under our Certificate of Incorporation, and approximately

72.0

million shares of common stock and

5.0

million shares of preferred stock available for issuance and

not

otherwise reserved.

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

–

Summary of Significant Accounting Policies

Principles of Consolidation

Business Combinations

may

differ materially from estimates.

Goodwill and Intangible Assets

not

amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value

may

be impaired. The following table represents identifiable intangible assets as of

March 31, 2019:

(in thousands)	Estimated Fair Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is

not

amortized. We perform an annual impairment test for goodwill and evaluate the recoverability whenever events or changes in circumstances indicate that the carrying value of goodwill

may

not

be fully recoverable. In making such assessment, qualitative factors are used to determine whether it is more likely than

not

that our fair value is less than our carrying value. If the estimated fair value is less than our carrying value, then an impairment loss is recorded.

Foreign Currency Transactions

The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are

not

denominated in the functional currency at exchange rates in effect at the end of each period. Gains and losses from the remeasurement of foreign currency transactions are recognized in other income (expense). Foreign currency transactions resulted in gains of approximately

$0.2

million for the

three

months ended

March 31, 2019.

There were

foreign currency transaction gains or losses for the

three

months ended

March 31, 2018.

Use of Estimates

Marketable Securities

320,

Investments—Debt and Equity Securities. Investments are recorded at fair value, with unrealized gains and losses included as a component of accumulated other comprehensive loss in stockholders’ equity and a component of total comprehensive loss in the consolidated statements of comprehensive loss, until realized. Realized gains and losses are included in other income (expense) on a specific-identification basis. For the

three

months ended

March 31, 2019,

we had

$11,000

in realized gains and

$40,000

in unrealized gains on marketable securities. There were

realized or unrealized gains or losses on investments for the

three

months ended

March 31, 2018.

We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is

not

recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if we have experienced a credit loss, have the intent to sell the investment, or if it is more likely than

not

that we will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period.

Leases

Effective

January 1, 2019,

we adopted ASC Topic

842,

Leases (ASC

842

), using the modified retrospective transition approach and utilizing the effective date as the date of initial application. Consequently, prior period balances and disclosures have

not

been restated and are presented in accordance with the previous guidance in ASC Topic

840,

Leases.

one

year are recognized on the balance sheet as operating lease right-of-use assets and current and non-current operating lease liabilities, as applicable. We elected

not

to recognize on the balance sheet leases with terms of

months or less. We typically only include the initial lease term in our assessment of a lease arrangement. Options to extend a lease are

not

included in our assessment unless there is reasonable certainty that we will renew.

may

be required for items such as incentives received. The interest rate implicit in our leases is typically

not

readily determinable. As a result, we utilize our incremental borrowing rate, which reflects the fixed rate at which we could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. In transition to ASC

842,

we utilized the remaining lease term of our leases in determining the appropriate incremental borrowing rates.

Restructured Debt Liability – Contingent Milestone Payment

In conjunction with the

November 2017

restructuring and retirement of long-term debt (s

ee,

Note

– Restructured Debt Liability), we established a

$15

million long-term liability for contingent AEROSURF regulatory and commercial milestone payments, beginning with the filing for marketing approval in the United States, potentially due under the Exchange and Termination Agreement dated as of

October 27, 2017 (

Exchange and Termination Agreement), between ourselves and affiliates of Deerfield Management Company L.P. (Deerfield). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are

not

achieved and the liability is written off as a gain on debt restructuring.

Research and Development

730,

Research and Development.

Net Loss per Common Share

March 31, 2019

and

2018,

the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of certain stock options and warrants was

15.2

million and

1.0

million shares, respectively. For the

three

months ended

March 31, 2019

and

2018,

all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Income Taxes

We account for income taxes in accordance with ASC Topic

740,

Accounting for Income Taxes, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities.

not

assured.

Recently Adopted Accounting Standards

February 2016,

the FASB issued Accounting Standards Update (ASU)

No.

2016

02,

Leases (ASU

2016

). ASU

2016

establishes ASC

842

which amends ASC

840,

Leases, by introducing a lessee model that requires balance sheet recognition for most leases and the disclosure of key information about leasing arrangements. ASC

842

was subsequently amended during

2018.

Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. We adopted the new standard using the required modified retrospective approach on

January 1, 2019

and used the effective date as its date of initial application. Consequently, financial information is

not

updated and the disclosures required under the new standard are

not

provided for dates and periods prior to

January 1, 2019.

Instead, the requirements of ASC

840

are presented for these prior periods.

ASC

842

provides several optional practical expedients in transition. We elected the package of practical expedients which allowed us to

not

reassess its existing conclusions on lease identification, classification, and initial direct costs. Further, we elected to utilize the short-term lease exemption for all leases with an original term of

months or less, for purposes of applying the recognition and measurement requirements of the new standard. We also elected the practical expedient to

not

separate lease and non-lease components for all our leases.

The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of

$2.2

million and

$2.0

million, respectively, related to our operating leases. The adoption of ASC

842

also resulted in the elimination of deferred rent of approximately

$72,000

and

$139,000

in accrued expenses and other long-term liabilities, respectively, in our condensed consolidated balance sheets. The adoption of the standard did

not

have a material impact on our condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. Refer to Note

– Leases, for our current lease commitments.

January 2017,

the FASB issued ASU

No.

2017

04,

Intangibles-Goodwill and Other (Topic

350

): Simplifying the Test for Goodwill Impairment. The new standard simplifies the subsequent measurement of goodwill by eliminating the

second

step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after

December 15, 2019

with early adoption permitted. We adopted this guidance on

January 1, 2019

and will apply it to our annual impairment test, and any interim impairment tests during the year ending

December 31, 2019.

Recently Issued Accounting Standards

August 2018,

the FASB issued ASU

No.

2018

13,

Fair Value Measurement (Topic

820

): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU

2018

), which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic

820.

Companies will

longer be required to disclose the amount of and reasons for transfers between Level

and Level

of the fair value hierarchy as well as the valuation processes of Level

fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level

fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level

fair value measurements. ASU

2018

is effective for fiscal years, and interim periods within those fiscal years, beginning after

December 15, 2019.

The amendments relating to additional disclosure requirements will be applied prospectively for only the most recent interim or annual period presented in the initial year of adoption. All other amendments will be applied retrospectively to all periods presented upon their effective date. We are currently evaluating the impact that the adoption of ASU

2018

will have on our consolidated financial statements.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - License Revenue with Affiliate

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note

–

License

evenue with

ffiliate

	Three Months Ended March 31,
(in thousands)	2019		2018

License revenue with affiliate	$	40	$	204

License revenue with affiliate for the

three

months ended

March 31, 2019

represents revenue from a License Agreement with Lee’s Pharmaceutical (HK) Ltd. (Lee’s (HK)), an affiliate of our largest shareholder, Lee’s Pharmaceutical Holdings Limited (Lee’s), and constitutes a contract with a customer accounted for in accordance with ASC Topic

606.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value of Financial Instruments

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note

–

Fair Value of Financial Instruments

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on

three

levels of inputs, of which the

first

two

are considered observable and the last unobservable, as follows:

	●	Level 1 – Quoted prices in active markets for identical assets and liabilities.
	●	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	March 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	2,053	$	2,053	$	-	$	-
U.S. Treasury notes		13,514		13,514		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	15,738	$	15,738	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	5,234	$	5,234	$	-	$	-
U.S. Treasury notes		19,912		19,912		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	25,317	$	25,317	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Loan Payable

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Short-term Debt [Text Block]

Note

–

Loan Payable

January 2018

and

March 2018,

LPH Investments Limited (LPH), an affiliate of Lee’s, agreed to lend us

$1.5

million and

$1.0

million, respectively, to support our AEROSURF development activities and sustain our operations while we sought to identify and advance

one

or more potential strategic initiatives as defined in the related loan agreements (Funding Event). The loans accrued interest at a rate of

per annum and would mature upon the earlier of the closing date of the Funding Event or

December 31, 2018.

To secure our obligations under these loans, we granted LPH a security interest in substantially all our assets pursuant to the terms of a Security Agreement with LPH dated

March 1, 2018 (

LPH Security Agreement). Effective

December 5, 2018,

LPH assigned all outstanding loans to us to LPH II Investment Limited (LPH II). In connection with the Private Placement Financing, we converted

$6.0

million of the then outstanding loan payable obligations to LPH II on the same terms as those of the investors in the private placement. Included in the conversion were the

$1.5

million and

$1.0

million loans.

Assumption of bank debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately

$4.5

million in a bank credit facility due in

March 2020.

September 2016,

CVie entered into a

-month revolving credit facility of approximately

$2.9

million with O-Bank Co., Ltd. to finance operating activities. The facility was later renewed and increased to approximately

$5.8

million in

September 2017.

The credit facility was guaranteed by Lee’s, which pledged bank deposits in the amount of

110%

of the actual borrowing amount. The guaranty was part of the facility; however, we do

not

have a written commitment from Lee’s to maintain the collateral. Interest, payable in cash on a monthly basis, is determined based on

-day TAIBOR (the Taipei Interbank Offer Rate) plus

0.91%.

The credit facility will expire on

September 11, 2019

and matures

six

months after the expiration date, on

March 11, 2020.

Although we reached an understanding with Lee’s that it would maintain the bank deposits securing its guaranty obligation under the credit facility, we do

not

have a written agreement with Lee’s requiring it to do so; therefore, the

$4.5

million outstanding under the facility has been classified as a current liability on the condensed consolidated balance sheets.

As of

March 31, 2019,

the outstanding principal was approximately

$4.5

million.

Assumption of Lee’s debt as part of the CVie Acquisition

As part of the CVie Acquisition, we assumed approximately

$3.5

million of debt payable to Lee’s Pharmaceutical International Limited (Lee’s International).

From

April 24, 2018

November 16, 2018,

CVie entered into

four

separate agreements to borrow an aggregate of approximately

$3.5

million from Lee’s International. The terms of the loan agreements are identical where the interest, payable in cash upon maturity, is

per annum and each of the

four

separate loans will mature

one

year from the effective date as follows:

$0.5

million in

April 2019;

$0.3

million in

September 2019;

$0.2

million in

October 2019;

and

$2.5

million in

November 2019.

During the quarter ended

March 31, 2019,

we made payments of

$0.45

million against the

April 2018

loan and paid the remaining

$50,000

balance plus accrued interest in

April 2019.

As of

March 31, 2019,

the outstanding principal of the loans with Lee’s was

$3.0

million.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Restructured Debt Liability

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Long-term Debt [Text Block]

Note

–

Restructured

ebt

iability

	March 31,		December 31,
(in thousands)	2019		2018

Restructured debt liability - contingent milestone payments	$	15,000	$	15,000

November 1, 2017,

we and Deerfield entered into an Exchange and Termination Agreement pursuant to which (i) promissory notes evidencing a loan with affiliates of Deerfield Management Company L.P. (Deerfield Loan) in the aggregate principal amount of

$25

million and (ii) warrants to purchase up to

25,000

shares of our common stock at an exercise price of

$786.80

per share held by Deerfield were cancelled in consideration for (i) a cash payment in the aggregate amount of

$2.5

million, (ii)

71,111

shares of common stock, representing

of fully-diluted shares outstanding (as defined in the Exchange and Termination Agreement) on the closing date, and (iii) the right to receive certain milestone payments based on achievement of specified AEROSURF development and commercial milestones, which, if achieved, could potentially total up to

$15

million. In addition, a related security agreement, pursuant to which Deerfield held a security interest in substantially all of our assets, was terminated. We established a

$15

million long-term liability for the contingent milestone payments potentially due to Deerfield under the Exchange and Termination Agreement (

see

, Note

– Summary of Significant Accounting Policies). The liability has been recorded at full value of the contingent milestones and will continue to be carried at full value until the milestones are achieved and paid or milestones are

not

achieved and the liability is written off as a gain on debt restructuring.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

Note

–

Stock Options and Stock-Based Employee Compensation

three

years. We recognize restricted stock unit awards to employees and non-employee directors based on their fair value on the date of grant. Compensation expense related to restricted stock unit awards is recognized ratably over the vesting period, which typically has been between approximately

six

months.

A summary of activity under our long-term incentive plan is presented below:

				Weighted-		Weighted- Average
(in thousands, except for weighted-average data)				Average		Remaining
Stock Options	Shares			Exercise Price		Contractual Term (In Yrs)

Outstanding at January 1, 2019		4,417		$	6.73
Granted		824			4.11
Forfeited or expired		(4	)		576.33
Outstanding at March 31, 2019		5,237		$	5.91		9.7

Vested and exercisable at March 31, 2019		69		$	130.39		6.7

Vested and expected to vest at March 31, 2019		4,942		$	5.89		9.7

(in thousands, except for weighted-average data)

Restricted Stock Units	Shares			Weighted- Average Grant Date Fair Value

Unvested at January 1, 2019		151		$	4.29
Awarded		249			3.95
Vested		(95	)		3.95
Cancelled		(144	)		4.33
Unvested at March 31, 2019		161		$	4.22

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

	Three Months Ended March 31,
	2019

Weighted average expected volatility		96	%
Weighted average expected term (in years)		6.5
Weighted average risk-free interest rate		2.60	%
Expected dividends		-

The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

	Three Months Ended March 31,
(in thousands)	2019		2018

Research and development	$	489	$	110
General and administrative		1,041		308
Total	$	1,530	$	418

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Leases

3 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

Note

–

Leases

Our operating leases consist primarily of facility leases for our operations in Warrington, Pennsylvania and Taipei, Taiwan.

We maintain our corporate headquarters and operations in Warrington, Pennsylvania, with a remaining non-cancelable term of approximately

three

years. The facility serves as the main operating facility for drug and device development, regulatory, analytical technical services, research and development, and administration. We also maintain offices in Taipei, Taiwan, the former headquarters of CVie Therapeutics, where we perform certain manufacturing development and preclinical activities related to our cardiovascular drug product candidates.

The following table contains a summary of the lease costs recognized under ASC

842

and other information pertaining to our operating leases for the

three

months ended

March 31, 2019:

	Three Months Ended March 31,
(in thousands)	2019

Operating lease cost	$	238
Variable lease cost		7
Total lease cost	$	245

Other Information
Operating cash flows used for operating leases	$	253
Weighted average remaining lease term (in years)		2.9
Weighted average incremental borrowing rate		9.00	%

Future minimum lease payments under our non-cancelable operating leases as of

March 31, 2019,

are as follows:

	Three Months Ended March 31,
(in thousands)	2019

2019 (excluding the three months ended March 31, 2019)	$	699
2020		666
2021		654
2022		194
2023		28
Thereafter		-
Total lease payments		2,241
Less imputed interest		(260	)
Total operating lease liabilities at March 31, 2019		1,981

The total aggregate base rental payments remaining under the leases as of

December 31, 2018

were approximately

$2.1

million.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Business Combinations Policy [Policy Text Block]

Business Combinations

may

differ materially from estimates.

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Intangible Assets

not

amortized but reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value

may

be impaired. The following table represents identifiable intangible assets as of

March 31, 2019:

(in thousands)	Estimated Fair Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

Goodwill represents the excess of the purchase price over the fair value assets acquired and liabilities assumed in a business combination and is

not

amortized. We perform an annual impairment test for goodwill and evaluate the recoverability whenever events or changes in circumstances indicate that the carrying value of goodwill

may

not

be fully recoverable. In making such assessment, qualitative factors are used to determine whether it is more likely than

not

that our fair value is less than our carrying value. If the estimated fair value is less than our carrying value, then an impairment loss is recorded.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Transactions

The functional currency for our foreign subsidiaries is US dollars. We remeasure monetary assets and liabilities that are

not

$0.2

million for the

three

months ended

March 31, 2019.

There were

foreign currency transaction gains or losses for the

three

months ended

March 31, 2018.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Marketable Securities, Policy [Policy Text Block]

Marketable Securities

320,

three

months ended

March 31, 2019,

we had

$11,000

in realized gains and

$40,000

in unrealized gains on marketable securities. There were

realized or unrealized gains or losses on investments for the

three

months ended

March 31, 2018.

We review investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is

not

Lessee, Leases [Policy Text Block]

Leases

Effective

January 1, 2019,

we adopted ASC Topic

842,

Leases (ASC

842

), using the modified retrospective transition approach and utilizing the effective date as the date of initial application. Consequently, prior period balances and disclosures have

not

been restated and are presented in accordance with the previous guidance in ASC Topic

840,

Leases.

one

year are recognized on the balance sheet as operating lease right-of-use assets and current and non-current operating lease liabilities, as applicable. We elected

not

to recognize on the balance sheet leases with terms of

months or less. We typically only include the initial lease term in our assessment of a lease arrangement. Options to extend a lease are

not

included in our assessment unless there is reasonable certainty that we will renew.

may

be required for items such as incentives received. The interest rate implicit in our leases is typically

not

842,

we utilized the remaining lease term of our leases in determining the appropriate incremental borrowing rates.

Restructured Debt Liability, Contingent Milestone Payment, Policy [Policy Text Block]

Restructured Debt Liability – Contingent Milestone Payment

In conjunction with the

November 2017

restructuring and retirement of long-term debt (s

ee,

Note

– Restructured Debt Liability), we established a

$15

October 27, 2017 (

not

achieved and the liability is written off as a gain on debt restructuring.

Research and Development Expense, Policy [Policy Text Block]

Research and Development

730,

Research and Development.

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Common Share

March 31, 2019

and

2018,

the number of shares of common stock potentially issuable upon the conversion of preferred stock or exercise of certain stock options and warrants was

15.2

million and

1.0

million shares, respectively. For the

three

months ended

March 31, 2019

and

2018,

all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Income Tax, Policy [Policy Text Block]

Income Taxes

We account for income taxes in accordance with ASC Topic

740,

not

assured.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

February 2016,

the FASB issued Accounting Standards Update (ASU)

No.

2016

02,

Leases (ASU

2016

). ASU

2016

establishes ASC

842

which amends ASC

840,

Leases, by introducing a lessee model that requires balance sheet recognition for most leases and the disclosure of key information about leasing arrangements. ASC

842

was subsequently amended during

2018.

January 1, 2019

and used the effective date as its date of initial application. Consequently, financial information is

not

updated and the disclosures required under the new standard are

not

provided for dates and periods prior to

January 1, 2019.

Instead, the requirements of ASC

840

are presented for these prior periods.

ASC

842

provides several optional practical expedients in transition. We elected the package of practical expedients which allowed us to

not

months or less, for purposes of applying the recognition and measurement requirements of the new standard. We also elected the practical expedient to

not

separate lease and non-lease components for all our leases.

The adoption of this standard resulted in the recognition of operating lease liabilities and related right-of-use assets on our condensed consolidated balance sheets of

$2.2

million and

$2.0

million, respectively, related to our operating leases. The adoption of ASC

842

also resulted in the elimination of deferred rent of approximately

$72,000

and

$139,000

in accrued expenses and other long-term liabilities, respectively, in our condensed consolidated balance sheets. The adoption of the standard did

not

have a material impact on our condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. Refer to Note

– Leases, for our current lease commitments.

January 2017,

the FASB issued ASU

No.

2017

04,

Intangibles-Goodwill and Other (Topic

350

): Simplifying the Test for Goodwill Impairment. The new standard simplifies the subsequent measurement of goodwill by eliminating the

second

step of the goodwill impairment test. This ASU will be applied prospectively and is effective for annual or interim goodwill impairment tests in fiscal years beginning after

December 15, 2019

with early adoption permitted. We adopted this guidance on

January 1, 2019

and will apply it to our annual impairment test, and any interim impairment tests during the year ending

December 31, 2019.

Recently Issued Accounting Standards

August 2018,

the FASB issued ASU

No.

2018

13,

Fair Value Measurement (Topic

820

): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (ASU

2018

), which removes, adds and modifies certain disclosure requirements for fair value measurements in Topic

820.

Companies will

longer be required to disclose the amount of and reasons for transfers between Level

and Level

of the fair value hierarchy as well as the valuation processes of Level

fair value measurements. However, companies will be required to additionally disclose the changes in unrealized gains and losses included in other comprehensive income for recurring Level

fair value measurements and the range and weighted average of assumptions used to develop significant unobservable inputs for Level

fair value measurements. ASU

2018

is effective for fiscal years, and interim periods within those fiscal years, beginning after

December 15, 2019.

2018

will have on our consolidated financial statements.

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 4 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

(in thousands)	Estimated Fair Value

Istaroxime drug candidate	$	22,340
Rostafuroxin drug candidate		54,750
Total	$	77,090

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 5 - License Revenue with Affiliate (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2019		2018

License revenue with affiliate	$	40	$	204

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value of Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value		Fair value measurement using
	March 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	2,053	$	2,053	$	-	$	-
U.S. Treasury notes		13,514		13,514		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	15,738	$	15,738	$	-	$	-

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2018		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	5,234	$	5,234	$	-	$	-
U.S. Treasury notes		19,912		19,912		-		-
Certificate of deposit		171		171		-		-
Total Assets	$	25,317	$	25,317	$	-	$	-

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 8 - Restructured Debt Liability (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Schedule of Long-term Debt Instruments [Table Text Block]

	March 31,		December 31,
(in thousands)	2019		2018

Restructured debt liability - contingent milestone payments	$	15,000	$	15,000

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

				Weighted-		Weighted- Average
(in thousands, except for weighted-average data)				Average		Remaining
Stock Options	Shares			Exercise Price		Contractual Term (In Yrs)

Outstanding at January 1, 2019		4,417		$	6.73
Granted		824			4.11
Forfeited or expired		(4	)		576.33
Outstanding at March 31, 2019		5,237		$	5.91		9.7

Vested and exercisable at March 31, 2019		69		$	130.39		6.7

Vested and expected to vest at March 31, 2019		4,942		$	5.89		9.7

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

(in thousands, except for weighted-average data)

Restricted Stock Units	Shares			Weighted- Average Grant Date Fair Value

Unvested at January 1, 2019		151		$	4.29
Awarded		249			3.95
Vested		(95	)		3.95
Cancelled		(144	)		4.33
Unvested at March 31, 2019		161		$	4.22

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Three Months Ended March 31,
	2019

Weighted average expected volatility		96	%
Weighted average expected term (in years)		6.5
Weighted average risk-free interest rate		2.60	%
Expected dividends		-

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2019		2018

Research and development	$	489	$	110
General and administrative		1,041		308
Total	$	1,530	$	418

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 10 - Leases (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Lease, Cost [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2019

Operating lease cost	$	238
Variable lease cost		7
Total lease cost	$	245

Other Information
Operating cash flows used for operating leases	$	253
Weighted average remaining lease term (in years)		2.9
Weighted average incremental borrowing rate		9.00	%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

	Three Months Ended March 31,
(in thousands)	2019

2019 (excluding the three months ended March 31, 2019)	$	699
2020		666
2021		654
2022		194
2023		28
Thereafter		-
Total lease payments		2,241
Less imputed interest		(260	)
Total operating lease liabilities at March 31, 2019		1,981

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 1 - The Company and Description of Business (Details Textual)	Dec. 21, 2018 $ / shares shares	Mar. 31, 2019 $ / shares	Dec. 31, 2018 $ / shares
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001	$ 0.001	$ 0.001
CVie Investment [Member]
Business Acquisition, Share Exchange Ratio	0.3512
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares	16,265,060

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 3 - Liquidity Risks and Management's Plans (Details Textual) - USD ($) $ in Thousands	Dec. 21, 2018	Mar. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance		$ 2,053	$ 11,187
Debt Securities, Available-for-sale, Current, Total		13,514	13,959
Liabilities, Current, Total		16,960	$ 20,633
Loans Payable, Current, Total		$ 7,500
Private Placement Financing, Value	$ 39,000
Common Stock, Shares Authorized		120,000,000	120,000,000
Preferred Stock, Shares Authorized		5,000,000	5,000,000
Common Stock, Capital Shares Available for Issuance		72,000,000
Preferred Stock, Capital Shares Available for Issuance		5,000,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 4 - Summary of Significant Accounting Policies (Details Textual) - USD ($) shares in Millions	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Jan. 01, 2019	Dec. 31, 2018	Nov. 01, 2017
Foreign Currency Transaction Gain (Loss), before Tax, Total	$ 200,000	$ 0
Marketable Securities, Realized Gain (Loss), Total	11,000	0
Marketable Securities, Unrealized Gain (Loss), Total	40,000	$ 0
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000,000			$ 15,000,000
Number of Shares of Common Stock Potentially Issuable upon the Exercise of Stock Options and Warrants	15.2	1.0
Operating Lease, Right-of-Use Asset	$ 1,788,000
Operating Lease, Liability, Total	1,981,000
Accrued Liabilities, Current, Total	5,247,000			6,465,000
Other Liabilities, Noncurrent, Total	63,000			175,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 2,200,000
Operating Lease, Liability, Total			2,000,000
Accrued Liabilities, Current, Total			(72,000)
Other Liabilities, Noncurrent, Total			$ (139,000)
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000,000			$ 15,000,000
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Liability for Contingent Milestone Payment, Noncurrent					$ 15,000,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Indefinite intangible asset	$ 77,090	$ 77,090
Istaroxime Drug Candidate [Member]
Indefinite intangible asset	22,340
Rostafuroxin Drug Candidate [Member]
Indefinite intangible asset	$ 54,750

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
License [Member]
License revenue with affiliate	$ 40	$ 204

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 2,053	$ 5,234
Total Assets	15,738	25,317
Certificates of Deposit [Member]
Certificate of deposit	171	171
US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents	13,514
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	2,053	5,234
Total Assets	15,738	25,317
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Certificate of deposit	171	171
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Cash and cash equivalents		19,912
Cash and cash equivalents	13,514
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Total Assets
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Certificate of deposit
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Cash and cash equivalents
Cash and cash equivalents

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 7 - Loan Payable (Details Textual) $ in Millions		1 Months Ended			3 Months Ended
Note 7 - Loan Payable (Details Textual) $ in Millions	Dec. 21, 2018 USD ($)	Apr. 30, 2019 USD ($)	Mar. 31, 2018 USD ($)	Jan. 31, 2018 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)	Nov. 16, 2018 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2016 TWD ($)
Repayments of Short-term Debt, Total					$ 447,000
Short-term Debt, Total					7,469,000		$ 7,974,000
Debt Payable to Lee's International [Member]
Debt Instrument, Interest Rate, Stated Percentage								4.00%
Debt Instrument, Face Amount								$ 3,500,000
Repayments of Short-term Debt, Total					450,000
Short-term Debt, Total					3,000,000
Debt Payable to Lee's International [Member] \| Subsequent Event [Member]
Repayments of Short-term Debt, Total		$ 50,000
Debt Payable to Lee's International [Member] \| Debt Maturing April 2019 [Member]
Debt Instrument, Face Amount								500,000
Debt Payable to Lee's International [Member] \| Debt Maturing September 2019 [Member]
Debt Instrument, Face Amount								300,000
Debt Payable to Lee's International [Member] \| Debt Maturing October 2019 [Member]
Debt Instrument, Face Amount								200,000
Debt Payable to Lee's International [Member] \| Debt Maturing November 2019 [Member]
Debt Instrument, Face Amount								$ 2,500,000
Debt Payable to Lee's International [Member] \| CVie Investments [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt	$ 3,500,000
Loan Payable Obligation Converted to LPH II [Member]
Debt Conversion, Original Debt, Amount	6,000,000
LPH [Member]
Proceeds from Issuance of Debt			$ 1,000,000	$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage							6.00%
LPH [Member] \| Loan Payable Obligation Converted to LPH II [Member] \| Debt Issued on January 2018 [Member]
Debt Conversion, Original Debt, Amount	1,500,000
LPH [Member] \| Loan Payable Obligation Converted to LPH II [Member] \| Debt Issued on March 2018 [Member]
Debt Conversion, Original Debt, Amount	$ 1,000,000
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Percent of Pledged Deposits Required	110.00%
Line of Credit, Current	$ 4,500,000				$ 4,500,000
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member] \| Taipei Interbank Offer Rate (TAIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	0.91%
O-Bank Co., Ltd. [Member] \| Revolving Credit Facility [Member] \| CVie Investments [Member]
Line of Credit Facility, Maximum Borrowing Capacity									$ 2,900,000	$ 5.8
O-Bank Co., Ltd. [Member] \| CVie Investments [Member] \| Revolving Credit Facility [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Total	$ 4,500,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 8 - Restructured Debt Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 01, 2017	Mar. 31, 2019	Dec. 31, 2018
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000
Deerfield Loan [Member]
Liability for Contingent Milestone Payment, Noncurrent		$ 15,000	$ 15,000
Deerfield Loan [Member] \| Exchange and Termination Agreement [Member] \| Deerfield Management, L.P. [Member]
Extinguishment of Debt, Amount	$ 25,000
Class of Warrant or Right, Number of Warrants Cancelled	25,000
Class of Warrant or Right, Exercise Price of Cancelled Warrants	$ 786.80
Repayments of Long-term Debt, Total	$ 2,500
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations	71,111
Stock Issued During Period, Shares, Cancellation of Debt and Warrant Obligations, Percentage of Fully-diluted Shares Outstanding	2.00%
Liability for Contingent Milestone Payment, Noncurrent	$ 15,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 8 - Restructured Debt Liability - Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000
Deerfield Loan [Member]
Restructured debt liability - contingent milestone payments	$ 15,000	$ 15,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) - The 2011 Long-term Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2019
Stock-based Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	3 years
Restricted Stock Units (RSUs) [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	180 days
Restricted Stock Units (RSUs) [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	1 year 180 days

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Shares Outstanding, Beginning Balance (in shares) \| shares	4,417
Weighted Average Exercise Price, Outstanding, at Beginning Period (in dollars per share) \| $ / shares	$ 6.73
Shares Granted (in shares) \| shares	824
Weighted Average Exercise Price, Granted (in dollars per share) \| $ / shares	$ 4.11
Shares Forfeited or Expired (in shares) \| shares	(4)
Weighted Average Exercise Price, Forfeited or Expired (in dollars per share) \| $ / shares	$ 576.33
Shares Outstanding, Ending Balance (in shares) \| shares	5,237
Weighted Average Exercise Price, Outstanding, at Ending Period (in dollars per share) \| $ / shares	$ 5.91
Weighted Average Remaining Contractual Life, Outstanding (Year)	9 years 255 days
Shares Vested and Exercisable (in shares) \| shares	69
Weighted Average Exercise Price, Vested and Exercisable (in dollars per share) \| $ / shares	$ 130.39
Weighted Average Remaining Contractual Life, Vested and Exercisable (Year)	6 years 255 days
Vested and expected to vest (in shares) \| shares	4,942
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share) \| $ / shares	$ 5.89
Weighted Average Remaining Contractual Life, Vested and Expected to Vest (Year)	9 years 255 days

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2019 $ / shares shares
Unvested, Beginning Balance (in shares) \| shares	151
Unvested, Beginning Balance (in dollars per share) \| $ / shares	$ 4.29
Awarded (in shares) \| shares	249
Awarded (in dollars per share) \| $ / shares	$ 3.95
Vested (in shares) \| shares	(95)
Vested (in dollars per share) \| $ / shares	$ 3.95
Cancelled (in shares) \| shares	(144)
Cancelled (in dollars per share) \| $ / shares	$ 4.33
Unvested, Ending Balance (in shares) \| shares	161
Unvested, Ending Balance (in dollars per share) \| $ / shares	$ 4.22

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2019
Weighted average expected volatility	96.00%
Weighted average expected term (Year)	6 years 182 days
Weighted average risk-free interest rate	2.60%
Expected dividends

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock-based compensation expense	$ 1,530	$ 418
Research and Development Expense [Member]
Stock-based compensation expense	489	110
General and Administrative Expense [Member]
Stock-based compensation expense	$ 1,041	$ 308

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 10 - Leases (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Lessee, Operating Lease, Liability, Payments, Due, Total	$ 2,241	$ 2,100

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 10 - Leases - Lease Costs (Details) $ in Thousands	3 Months Ended
Note 10 - Leases - Lease Costs (Details) $ in Thousands	Mar. 31, 2019 USD ($)
Operating lease cost	$ 238
Variable lease cost	7
Total lease cost	245
Operating cash flows used for operating leases	$ 253
Weighted average remaining lease term (in years) (Year)	2 years 328 days
Weighted average incremental borrowing rate	9.00%

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 10 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
2019 (excluding the three months ended March 31, 2019)	$ 699
2020	666
2021	654
2022	194
2023	28
Thereafter
Total lease payments	2,241	$ 2,100
Less imputed interest	(260)
Total operating lease liabilities at March 31, 2019	$ 1,981

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 110 202 1 false 43 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.windtreetx.com/20190331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-statements-of-comprehensive-loss-unaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-statements-of-changes-in-stockholders-equity-unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.windtreetx.com/20190331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - The Company and Description of Business Sheet http://www.windtreetx.com/20190331/role/statement-note-1-the-company-and-description-of-business Note 1 - The Company and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.windtreetx.com/20190331/role/statement-note-2-basis-of-presentation Note 2 - Basis of Presentation Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Liquidity Risks and Management's Plans Sheet http://www.windtreetx.com/20190331/role/statement-note-3-liquidity-risks-and-managements-plans- Note 3 - Liquidity Risks and Management's Plans Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Summary of Significant Accounting Policies Sheet http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies Note 4 - Summary of Significant Accounting Policies Notes 11 false false R12.htm 011 - Disclosure - Note 5 - License Revenue with Affiliate Sheet http://www.windtreetx.com/20190331/role/statement-note-5-license-revenue-with-affiliate Note 5 - License Revenue with Affiliate Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Fair Value of Financial Instruments Sheet http://www.windtreetx.com/20190331/role/statement-note-6-fair-value-of-financial-instruments Note 6 - Fair Value of Financial Instruments Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Loan Payable Sheet http://www.windtreetx.com/20190331/role/statement-note-7-loan-payable Note 7 - Loan Payable Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Restructured Debt Liability Sheet http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability Note 8 - Restructured Debt Liability Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation- Note 9 - Stock Options and Stock-based Employee Compensation Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Leases Sheet http://www.windtreetx.com/20190331/role/statement-note-10-leases Note 10 - Leases Notes 17 false false R18.htm 017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.windtreetx.com/20190331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies 18 false false R19.htm 018 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies-tables Note 4 - Summary of Significant Accounting Policies (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies 19 false false R20.htm 019 - Disclosure - Note 5 - License Revenue with Affiliate (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-5-license-revenue-with-affiliate-tables Note 5 - License Revenue with Affiliate (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-5-license-revenue-with-affiliate 20 false false R21.htm 020 - Disclosure - Note 6 - Fair Value of Financial Instruments (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-6-fair-value-of-financial-instruments-tables Note 6 - Fair Value of Financial Instruments (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-6-fair-value-of-financial-instruments 21 false false R22.htm 021 - Disclosure - Note 8 - Restructured Debt Liability (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability-tables Note 8 - Restructured Debt Liability (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability 22 false false R23.htm 022 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-tables Note 9 - Stock Options and Stock-based Employee Compensation (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation- 23 false false R24.htm 023 - Disclosure - Note 10 - Leases (Tables) Sheet http://www.windtreetx.com/20190331/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://www.windtreetx.com/20190331/role/statement-note-10-leases 24 false false R25.htm 024 - Disclosure - Note 1 - The Company and Description of Business (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-1-the-company-and-description-of-business-details-textual Note 1 - The Company and Description of Business (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-1-the-company-and-description-of-business 25 false false R26.htm 025 - Disclosure - Note 3 - Liquidity Risks and Management's Plans (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-3-liquidity-risks-and-managements-plans-details-textual Note 3 - Liquidity Risks and Management's Plans (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-3-liquidity-risks-and-managements-plans- 26 false false R27.htm 026 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies-details-textual Note 4 - Summary of Significant Accounting Policies (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies-tables 27 false false R28.htm 027 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-4-summary-of-significant-accounting-policies-intangible-assets-details Note 4 - Summary of Significant Accounting Policies - Intangible Assets (Details) Details 28 false false R29.htm 028 - Disclosure - Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-5-license-revenue-with-affiliate-disaggregation-of-revenue-details Note 5 - License Revenue with Affiliate - Disaggregation of Revenue (Details) Details 29 false false R30.htm 029 - Disclosure - Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-6-fair-value-of-financial-instruments-assets-and-liabilities-measured-at-fair-value-details Note 6 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value (Details) Details 30 false false R31.htm 030 - Disclosure - Note 7 - Loan Payable (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-7-loan-payable-details-textual Note 7 - Loan Payable (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-7-loan-payable 31 false false R32.htm 031 - Disclosure - Note 8 - Restructured Debt Liability (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability-details-textual Note 8 - Restructured Debt Liability (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability-tables 32 false false R33.htm 032 - Disclosure - Note 8 - Restructured Debt Liability - Long-term Debt (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-8-restructured-debt-liability-longterm-debt-details Note 8 - Restructured Debt Liability - Long-term Debt (Details) Details 33 false false R34.htm 033 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-details-textual Note 9 - Stock Options and Stock-based Employee Compensation (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-tables 34 false false R35.htm 034 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-summary-of-stock-option-activity-details Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Stock Option Activity (Details) Details 35 false false R36.htm 035 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-summary-of-restricted-stock-units-activity-details Note 9 - Stock Options and Stock-based Employee Compensation - Summary of Restricted Stock Units Activity (Details) Details 36 false false R37.htm 036 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-stock-options-valuation-assumptions-details Note 9 - Stock Options and Stock-based Employee Compensation - Stock Options Valuation Assumptions (Details) Details 37 false false R38.htm 037 - Disclosure - Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-9-stock-options-and-stockbased-employee-compensation-stockbased-compensation-expense-details Note 9 - Stock Options and Stock-based Employee Compensation - Stock-based Compensation Expense (Details) Details 38 false false R39.htm 038 - Disclosure - Note 10 - Leases (Details Textual) Sheet http://www.windtreetx.com/20190331/role/statement-note-10-leases-details-textual Note 10 - Leases (Details Textual) Details http://www.windtreetx.com/20190331/role/statement-note-10-leases-tables 39 false false R40.htm 039 - Disclosure - Note 10 - Leases - Lease Costs (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-10-leases-lease-costs-details Note 10 - Leases - Lease Costs (Details) Details 40 false false R41.htm 040 - Disclosure - Note 10 - Leases - Future Minimum Lease Payments (Details) Sheet http://www.windtreetx.com/20190331/role/statement-note-10-leases-future-minimum-lease-payments-details Note 10 - Leases - Future Minimum Lease Payments (Details) Details 41 false false All Reports Book All Reports wint-20190331.xml wint-20190331.xsd wint-20190331_cal.xml wint-20190331_def.xml wint-20190331_lab.xml wint-20190331_pre.xml http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 57 0001437749-19-010506-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-19-010506-xbrl.zip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end